<SEC-DOCUMENT>0001213900-19-006723.txt : 20190418
<SEC-HEADER>0001213900-19-006723.hdr.sgml : 20190418
<ACCEPTANCE-DATETIME>20190418172439
ACCESSION NUMBER:		0001213900-19-006723
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20190418
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190418
DATE AS OF CHANGE:		20190418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		19756680

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k041819_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
April 18, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52446</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275 Madison Avenue, 7th Floor</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New York, NY</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10016</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2019, Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with William Blair &amp; Company, L.L.C., <FONT STYLE="background-color: white">as
representative of the several underwriters named therein</FONT> (the &ldquo;Underwriters&rdquo;), relating to the issuance and
sale (the &ldquo;Offering&rdquo;) of 42,860,000 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, $0.001 par
value per share (the &ldquo;Common Stock&rdquo;), and warrants to purchase 42,860,000 shares of Common Stock (the &ldquo;Warrants&rdquo;).
Each share of Common Stock is being sold together with a warrant to purchase one share of Common Stock, at a price to the public
of $0.385 per share and related warrant (the &ldquo;Offering Price&rdquo;). Pursuant to the terms of the Underwriting Agreement,
the Underwriters have agreed to purchase the Shares and warrants from the Company at a price of $0.358 per share and related warrant.
The Warrants will be exercisable commencing on the issuance date at an exercise price equal to $0.50 per whole share of Common
Stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the
date of issuance. The Company may redeem the Warrants for $0.001 per warrant if its Common Stock closes above $1.50 per share for
ten consecutive days. <FONT STYLE="background-color: white">The Warrants are being issued pursuant to a common stock purchase warrant
(&ldquo;Form of Warrant&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from
the sale of the Shares and Warrants are expected to be approximately $16.5 million. Net proceeds to the Company, after deducting
the underwriting discounts and other estimated offering expenses payable by the Company, are expected to be approximately $15.1
million. The Offering is expected to close on April 23, 2019, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Offering is being made pursuant to
the Company&rsquo;s effective shelf registration statement on Form S-3 (File No.&nbsp;333-216748) filed with the Securities and
Exchange Commission on March&nbsp;16, 2017, and declared effective on October 12, 2017, including the base prospectus dated October
24, 2017 included therein and the related preliminary prospectus supplement and prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the
Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties,
and termination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Underwriting Agreement,
subject to certain exceptions, the Company and its directors and officers have agreed not to sell or otherwise dispose of any of
the Company&rsquo;s securities held by them for a period ending 90 days after the date of the final prospectus supplement relating
to the Offering without first obtaining the written consent of the Underwriters.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing is only a brief description
of the material terms of the Underwriting Agreement and Form of Warrant, does not purport to be a complete description of the rights
and obligations of the parties thereunder, and each is qualified in its entirety by reference to the Underwriting Agreement and
form of Warrant that are filed as Exhibits 1.1 and 4.1, respectively, to this Current Report on Form 8-K and incorporated by reference
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement has been attached
hereto as an exhibit to provide investors and security holders with information regarding its terms. It is not intended to provide
any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement
were made only for purposes of the Underwriting Agreement and as of specific dates, were solely for the benefit of the parties
to the Underwriting Agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified
by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legal opinion of The Matt Law Firm,
PLLC relating to the Common Stock and Warrants being offered is filed as Exhibit 5.1 to this Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2019, the Company issued a
press release announcing that it intended to make a public offering of shares of the Common Stock and Warrants. On April 18, 2019,
the Company issued a press release announcing the pricing and terms of the Offering. Copies of the two press releases are attached
hereto as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the rules and regulations of
the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibits 99.1 and 99.2 and information
set forth therein, is deemed to have been furnished and shall not be deemed to be &ldquo;filed&rdquo; under the Securities Exchange
Act of 1934.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9.01</B>&nbsp;<B>Financial Statements and Exhibits.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the rules and regulations of
the Securities and Exchange Commission, the attached exhibits are deemed to have been filed with the Securities and Exchange Commission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f8k041819ex1-1_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Underwriting Agreement, dated as of April 18, 2019,&nbsp;by and between Actinium Pharmaceuticals, Inc. and William Blair &amp; Company, L.L.C.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f8k041819ex5-1_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion of The Matt Law Firm, PLLC.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f8k041819ex4-1_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f8k041819ex5-1_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of The Matt Law Firm, PLLC (included in Exhibit 5.1).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f8k041819ex99-1_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by Actinium Pharmaceuticals, Inc. dated April 17, 2019.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f8k041819ex99-2_actinium.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by Actinium Pharmaceuticals, Inc. dated April 18, 2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 18, 2019</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Sandesh Seth</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO &amp; Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f8k041819ex1-1_actinium.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF APRIL 18, 2019, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND WILLIAM BLAIR & COMPANY, L.L.C.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Execution
Version</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock, par value $0.001 per share, and Warrants to Purchase Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Underwriting
Agreement </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
18, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
Blair &amp; Company, L.L.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
representative of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">named
in Schedule I hereto,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
William Blair&nbsp;&amp; Company, L.L.C.<BR>
150 North Riverside Plaza<BR>
Chicago, Illinois 60606</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), proposes, subject to the terms and conditions
stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the &ldquo;<B><I>Underwriters</I></B>&rdquo;),
for whom William Blair &amp; Company, L.L.C. is acting as representative (the &ldquo;<B><I>Representative</I></B>&rdquo; or &ldquo;you&rdquo;),
an aggregate of (i) 42,860,000 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of common stock, par value $0.001 per share (the
&ldquo;<B><I>Common Stock</I></B>&rdquo;) of the Company and (ii) warrants to purchase up to 42,860,000 shares of Common Stock
in the form set forth on <U>Exhibit A</U> (the &ldquo;<B><I>Warrants</I></B>&rdquo; and, together with the Shares, the &ldquo;<B><I>Securities</I></B>&rdquo;).
Each Share is being sold together with a Warrant to purchase one share of Common Stock at an exercise price of $0.50 per whole
share of Common Stock. The shares of Common Stock underlying the Warrants are herein called the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company understands that the Underwriters propose to make a public offering of their respective portions of the Securities as
soon as you deem advisable. &nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Company represents and warrants to, and agrees with, each of the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A registration statement on Form S-3 (File No.&nbsp;333-216748) (the &ldquo;<B><I>Initial Registration Statement</I></B>&rdquo;)
in respect of the Securities has been filed with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;);
the Initial Registration Statement and any post-effective amendment thereto, each in the form heretofore delivered to you and,
excluding exhibits to the Initial Registration Statement, but including all documents incorporated by reference in the prospectus
included therein, have been declared effective by the Commission in such form; other than a registration statement, if any, increasing
the size of the offering (a &ldquo;<B><I>Rule 462(b) Registration Statement</I></B>&rdquo;), filed pursuant to Rule 462(b) under
the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), which became effective upon filing, no other document
with respect to the Initial Registration Statement or document incorporated by reference therein has heretofore been filed, or
transmitted for filing, with the Commission and no stop order suspending the effectiveness of the Initial Registration Statement,
any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for
that purpose has been initiated or, to the Company&rsquo;s knowledge, threatened by the Commission (the base prospectus filed
as part of the Initial Registration Statement, in the form in which it has most recently been filed with the Commission on or
prior to the date of this Agreement relating to the Securities, is hereinafter called the &ldquo;<B><I>Basic Prospectus</I></B>&rdquo;;
any preliminary prospectus (including any preliminary prospectus supplement) relating to the Securities filed with the Commission
pursuant to Rule 424(b) under the Act is hereinafter called a &ldquo;<B><I>Preliminary Prospectus</I></B>&rdquo;; the various
parts of the Initial Registration Statement and the Rule 462(b) Registration Statement, if any, including all exhibits thereto
and including any prospectus supplement relating to the Securities that is filed with the Commission and deemed by virtue of Rule
430B under the Act to be part of the Initial Registration Statement, each as amended at the time such part of the Initial Registration
Statement became effective or such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective,
are hereinafter collectively called the &ldquo;<B><I>Registration Statement</I></B>&rdquo;; the Basic Prospectus, as amended and
supplemented immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof), is hereinafter called the &ldquo;<B><I>Pricing
Prospectus</I></B>&rdquo;; the form of the final prospectus relating to the Securities filed with the Commission pursuant to Rule
424(b) under the Act, is hereinafter called the &ldquo;<B><I>Prospectus</I></B>&rdquo;; any reference herein to the Basic Prospectus,
the Pricing Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item&nbsp;12 of Form S-3 under the Act, as of the date of such prospectus; any reference to any
amendment or supplement to the Basic Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and
include any post-effective amendment to the Registration Statement, any prospectus supplement relating to the Securities filed
with the Commission pursuant to Rule 424(b) under the Act and any documents filed under the Securities Exchange Act of 1934, as
amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), and incorporated therein, in each case after the date of the Basic Prospectus,
such Preliminary Prospectus or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement
shall be deemed to refer to and include any annual report of the Company filed pursuant to Section&nbsp;13(a) or 15(d) of the
Exchange Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement;
and any &ldquo;issuer free writing prospectus&rdquo; as defined in Rule 433 under the Act relating to the Securities is hereinafter
called an &ldquo;<B><I>Issuer Free Writing Prospectus</I></B>&rdquo;; and any Issuer Free Writing Prospectus that is intended
for general distribution to prospective investors, as evidenced by its being so specified on Schedule II(a) hereto, is hereinafter
called a &ldquo;<B><I>General Use Issuer Free Writing Prospectus</I></B>&rdquo;;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued
by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements
of the Act and the rules and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply
to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by
an Underwriter through the Representative expressly for use therein, it being understood and agreed that the only such information
provided by any Underwriter through the Representative is that identified as such in Section 9(b);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
For the purposes of this Agreement, the &ldquo;<B><I>Applicable Time</I></B>&rdquo; is 8:40 a.m. (New York City time) on the date
of this Agreement. The Pricing Prospectus, as supplemented by the information listed in Schedule II(c) hereto and each General
Use Issuer Free Writing Prospectus, taken together (collectively, the &ldquo;<B><I>Pricing Disclosure Package</I></B>&rdquo;),
including any prospectus wrapper attached thereto, as of the Applicable Time, did not include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading; and each Issuer Free Writing Prospectus does not conflict with the information contained
in the Registration Statement, the Pricing Disclosure Package or the Prospectus and each such Issuer Free Writing Prospectus,
as supplemented by and taken together with the Pricing Disclosure Package as of the Applicable Time, did not include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall
not apply to statements or omissions made in an Issuer Free Writing Prospectus in reliance upon and in conformity with information
furnished in writing to the Company by an Underwriter through the Representative expressly for use therein, it being understood
and agreed that the only such information provided by any Underwriter through the Representative is that identified as such in
Section 9(b);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The documents incorporated by reference in the Pricing Disclosure Package and the Prospectus, when they became effective or were
filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Act or the Exchange
Act, as applicable, and the rules and regulations of the Commission thereunder, and none of such documents contained an untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; any further documents so filed and incorporated by reference in the Prospectus or any further amendment
or supplement thereto, when such documents become effective or are filed with the Commission, as the case may be, will conform
in all material respects to the requirements of the Act or the Exchange Act, as applicable, and the rules and regulations of the
Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and
warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in
writing to the Company by an Underwriter through the Representative expressly for use therein, it being understood and agreed
that the only such information provided by any Underwriter through the Representative is that identified as such in Section 9(b);
and no such documents were filed with the Commission since the Commission&rsquo;s close of business on the business day immediately
prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule II(b) hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement
and the Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the
Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement
and as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in
reliance upon and in conformity with information furnished in writing to the Company by an Underwriter through the Representative
expressly for use therein, it being understood and agreed that the only such information provided by any Underwriter through the
Representative is that identified as such in Section&nbsp;9(b);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The financial statements of the Company (including all notes and schedules thereto) included in the Registration Statement and
the Pricing Disclosure Package present fairly the financial position of the Company and its consolidated subsidiaries at the dates
indicated, and the balance sheet, statement of operations, stockholders&rsquo; equity and cash flows of the Company and its consolidated
subsidiaries for the periods specified and such financial statements and related schedules and notes thereto, have been prepared
in conformity with generally accepted accounting principles, consistently applied throughout the periods involved. The summary
and selected financial data included in the Pricing Disclosure Package present fairly the information shown therein at the respective
dates and for the respective periods specified and have been presented on a basis consistent with the consolidated financial statements
set forth in the Pricing Disclosure Package and other financial information. No other financial statements or supporting schedules
are required to be included in the Registration Statement or the Pricing Disclosure Package. The other financial and related statistical
information included in the Registration Statement and the Pricing Disclosure Package presents fairly in all material respects
the information included therein and has been prepared on a basis consistent with that of the financial statements that are included
in the Pricing Disclosure Package and the books and records of the respective entities presented therein. All disclosures contained
in the Registration Statement and the Pricing Disclosure Package regarding &ldquo;non-GAAP financial measures&rdquo; (as such
term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation
S-K of the Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The statistical and market-related data included in the Registration Statement, the Preliminary Prospectus and the Pricing Disclosure
Package, are based on or derived from sources that the Company believes to be reliable and accurate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Except as (i) described in the Registration Statement, the Preliminary Prospectus and the Pricing Disclosure Package or (ii) would
not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect (as hereinafter defined), (A) the Company
and each of its subsidiaries have filed all United States federal, state, local and foreign income tax returns required by law
to be filed through the date hereof and all taxes shown by such returns or otherwise assessed, which are due and payable, have
been paid; and (B) there is no deficiency that has been, or could reasonably be expected to be, asserted against the Company or
any of its subsidiaries or any of their respective properties or assets other than tax deficiencies that the Company or any of
its subsidiaries are contesting in good faith and as to which adequate reserves have been established in accordance with GAAP;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Neither the Company nor any of its subsidiaries has sustained since the date of the latest audited financial statements included
or incorporated by reference in the Pricing Disclosure Package any material loss or interference with its business, direct or
contingent, including from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute
or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Disclosure Package;
and, since the respective dates as of which information is given in the Registration Statement and the Pricing Disclosure Package,
there has not been (i) any change in the capital stock or long-term debt of the Company or any of its subsidiaries, taken as a
whole (other than changes pursuant to agreements or employee benefit plans or in connection with the exercise of options or warrants,
in each case as described or referred to in the Pricing Disclosure Package) or (ii) or any material adverse change, or any development
involving a prospective material adverse change, in or affecting the properties, business, management, prospects, operations,
earnings, assets, liabilities or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole (a &ldquo;<B><I>Material
Adverse Effect</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company and its subsidiaries have good and marketable title to all real property owned by them and have good title to all
other property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described
in the Pricing Disclosure Package or such as do not materially affect the value of such property and do not interfere with the
use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held
under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by
the Company and its subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Except as disclosed in the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries is in
violation of any statute, any rule, regulation, decision or order of any Governmental Authority or any court, domestic or foreign,
relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the
environment or human exposure to hazardous or toxic substances (collectively, <B><I>&ldquo;Environmental Laws&rdquo;</I></B>),
owns or operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any
off-site disposal or contamination pursuant to any Environmental Laws, or is subject to any claim relating to any Environmental
Laws, which violation, contamination, liability or claim would individually or in the aggregate, have a Material Adverse Effect;
and the Company is not aware of any pending investigation which might lead to such a claim. Neither the Company nor any of its
subsidiaries anticipates incurring any material capital expenditures relating to compliance with Environmental Laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company (i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State
of Delaware, with corporate power and corporate authority to own its properties and conduct its business as described in the Pricing
Disclosure Package and (ii) has been duly qualified as a foreign corporation for the transaction of business and is in good standing
under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such
qualification, except in the case of clause (ii), where the failure to be so qualified or in good standing would not have a Material
Adverse Effect; and each subsidiary of the Company (x) has been duly incorporated or formed, as the case may be, and is validly
existing as a corporation or limited liability company, as applicable, in good standing under the laws of its jurisdiction of
incorporation or formation, with the company power and authority to own its properties and conduct its business as described in
the Pricing Disclosure Package and (y) has been duly qualified as a foreign corporation or limited liability company for the transaction
of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts
any business so as to require such qualification, except in the case of clause (y), where the failure to be so qualified or in
good standing would not have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
This Agreement has been duly authorized, executed and delivered by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company has an authorized capitalization as set forth in the Pricing Disclosure Package under the caption &ldquo;Description
of Capital Stock&rdquo; and all of the issued shares of capital stock of the Company have been duly authorized and validly issued
and are fully paid and non-assessable and conform to the description of the Common Stock contained in the Pricing Disclosure Package
and the Prospectus and all of the issued shares of capital stock of each subsidiary of the Company have been duly authorized and
validly issued, are fully paid and non-assessable and (except for directors&rsquo; qualifying shares) are owned directly or indirectly
by the Company, free and clear of all liens, encumbrances, equities or claims and there are no options, warrants or other rights
to acquire shares of capital stock of any subsidiary of the Company; with respect to equity-based awards (the &ldquo;<B><I>Awards</I></B>&rdquo;)
granted pursuant to the equity-based compensation plans of the Company (the &ldquo;<B><I>Company Stock Plans</I></B>&rdquo;),
(i)&nbsp;each Award intended to qualify as an &ldquo;incentive stock option&rdquo; under Section&nbsp;422 of the Internal Revenue
Code so qualifies, (ii)&nbsp;each grant of an Award was duly authorized no later than the date on which the grant of such Award
was by its terms to be effective (the &ldquo;<B><I>Grant Date</I></B>&rdquo;) by all necessary corporate action, including, as
applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any
required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant
(if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms
of the Company Stock Plans, (iv)&nbsp;the per share exercise price of each Award was equal to the fair market value of a share
of Common Stock, as determined in good faith by the Board of Directors on the effective Grant Date and (v)&nbsp;each such grant
was properly accounted for in accordance with U.S. GAAP;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
The Securities to be issued and sold by the Company to the Underwriters hereunder have been duly authorized and, when issued and
delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and non-assessable and will
conform to the description of the Securities contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
the Warrant Shares have been duly authorized and reserved for issuance pursuant to the terms of the Warrants, and when issued
by the Company upon valid exercise of the Warrants and payment of the exercise price, will be validly issued, fully paid and nonassessable
and will conform to the description of the Warrant Shares contained in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; and the issuance of the Securities and the Warrant Shares is not subject to any preemptive or similar rights
that have not been waived or complied with;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
The issue and sale of the Securities, the issuance of the Warrant Shares upon exercise of the Warrants and the compliance by the
Company with its obligations under this Agreement and the consummation of the transactions herein contemplated (A)&nbsp;will not
conflict with or result in a material breach or violation of any of the terms or provisions of, or constitute a material default
under, any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which the Company or
any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property
or assets of the Company or any of its subsidiaries is subject, (B)&nbsp;will not violate any of the provisions of the Certificate
of Incorporation or Bylaws of the Company, or the organizational documents of any subsidiary, or (C)&nbsp;will not violate any
statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any
of its subsidiaries or any of their properties, and (D)&nbsp;will not require any consent, approval, authorization, order, registration
or qualification of or with any court, governmental agency or body or third party, except for (x) such consents, approvals, authorizations,
orders, registrations or qualifications that have been obtained or made and are in full force and effect, (y) the registration
under the Act of the Securities and the Warrant Shares, the approval by the Financial Industry Regulatory Authority (&ldquo;<B><I>FINRA</I></B>&rdquo;)
of the underwriting terms and arrangements, and (z) such consents, approvals, authorizations, orders, registrations or qualifications
as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Securities
by the Underwriters and the issuance of the Warrant Shares upon exercise of the Warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
Neither the Company nor any of its subsidiaries is (A)&nbsp;in violation of its Certificate of Incorporation, Bylaws or other
organizational documents or (B)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition
contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party
or by which it or any of its properties may be bound, except in the case of clause (B), to the extent that such default would
not have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
The statements set forth in the Pricing Disclosure Package and Prospectus under the caption &ldquo;Description of Capital Stock,&rdquo;
insofar as they purport to constitute a summary of the terms of the Common Stock, under the caption &ldquo;Underwriting,&rdquo;
insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and complete in
all material respects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
Other than as set forth in the Pricing Disclosure Package, there are no legal or governmental proceedings pending to which the
Company or any of its subsidiaries or, to the knowledge of the Company, any officer or director of the Company is a party or of
which any property or assets of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company
or any of its subsidiaries or any officer or director, would individually or in the aggregate reasonably be expected to have a
Material Adverse Effect; and, to the Company&rsquo;s knowledge, no such proceedings are threatened by governmental authorities
or threatened by others;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds thereof,
will not be an &ldquo;investment company,&rdquo; as such term is defined in the Investment Company Act of 1940, as amended (the
&ldquo;<B><I>Investment Company Act</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
At the earliest time after the filing of the Initial Registration Statement that the Company or another offering participant made
a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Securities, the Company was not and is not, as of
the date hereof, an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 under the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Marcum LLP, who have audited certain financial statements of the Company and its subsidiaries, and have audited the Company&rsquo;s
internal control over financial reporting and management&rsquo;s assessment thereof, is an independent registered public accounting
firm with respect to the Company as required by the Act and the rules and regulations of the Commission thereunder and the Public
Company Accounting Oversight Board (United States) (the &ldquo;<B><I>PCAOB</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the
Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company&rsquo;s principal executive
officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles. The Company&rsquo;s internal control over financial reporting is effective and the Company is not aware
of any &ldquo;significant deficiencies&rdquo; or &ldquo;material weaknesses&rdquo; (each as defined by the PCAOB) in its internal
control over financial reporting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
The Company&rsquo;s board of directors meets the independence requirements of, and has established an audit committee that meets
the independence requirements of, the rules and regulations of the Commission and the NYSE American stock exchange (&ldquo;<B><I>NYSE
American</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
Since the date of the latest audited financial statements included or incorporated by reference in the Pricing Disclosure Package,
there has been no change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that
comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material
information relating to the Company and its subsidiaries is made known to the Company&rsquo;s principal executive officer and
principal financial officer by others within those entities; and such disclosure controls and procedures are effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
Except to the extent as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
or its subsidiaries owns, possesses, or can acquire on reasonable terms, all Intellectual Property necessary for the conduct of
the Company&rsquo;s or any subsidiary&rsquo;s business as now conducted or as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus to be conducted, and there are no unreleased liens or security interests which have been
filed against any of the patents owned by the Company or its subsidiaries.&nbsp; Furthermore, (A) to the knowledge of the Company,
there is no infringement, misappropriation or violation by third parties of any such Intellectual Property; (B) there is no pending
or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&rsquo;s or
any subsidiary&rsquo;s rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form
a reasonable basis for any such claim; (C) the Intellectual Property owned by the Company or its subsidiaries, and to the knowledge
of the Company, the Intellectual Property licensed to the Company or its subsidiaries, has not been adjudged invalid or unenforceable,
in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim
by others challenging the validity or scope of any such Intellectual Property, and the Company is not aware of any facts which
would form a reasonable basis for any such claim; (D) there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates
any Intellectual Property or other proprietary rights of others, neither the Company nor any of its subsidiaries has received
any written notice of such claim and the Company is unaware of any other fact which would form a reasonable basis for any such
claim; (E) the Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property
has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect; (F) the drug candidates
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as under development by the Company
or its subsidiaries fall within the scope of the claims of one or more patents or applications relating to the drug candidate
or its intended use owned by, or exclusively licensed to, the Company or its subsidiaries; and (G) to the Company&rsquo;s knowledge,
no employee of the Company or any of its subsidiaries is in or has ever been in violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company or any of its subsidiaries or actions undertaken by the employee while employed with the Company or
any of its subsidiaries.&nbsp; <B><I>&ldquo;Intellectual Property&rdquo;</I></B> shall mean all patents, patent applications,
trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain
names, technology, know-how and other intellectual property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
There are no off-balance sheet arrangements (as defined in Regulation&nbsp;S-K Item&nbsp;303(a)(4)(ii)) that may have a material
current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations, liquidity,
capital expenditures or capital resources;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
The Company and each of its subsidiaries have complied, and are presently in compliance, in all material respects, with its privacy
and security policies, and with all obligations, laws and regulations regarding the collection, use, transfer, storage, protection,
disposal and/or disclosure of personally identifiable information and/or any other information collected from or provided by third
parties. The Company and its subsidiaries have taken commercially reasonable steps to protect the information technology systems
and data used in connection with the operation of the Company and/or its subsidiaries. The Company and its subsidiaries have used
reasonable efforts to establish, and have established, commercially reasonable disaster recovery and security plans, procedures
and facilities for the business, including, without limitation, for the information technology systems and data held or used by
or for the Company and/or any of its subsidiaries. Except as set forth in the Pricing Disclosure Package and the Prospectus, there
has been no security breach or attack or other compromise of or relating to any such information technology system or data which
would reasonably be expected to have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as are, in the Company&rsquo;s reasonable judgment, prudent and customary in the businesses in which
they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for;
and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business at a cost that would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
There are no contracts or other documents which are required to be described in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as
required;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
Except as disclosed in the Pricing Disclosure Package, there are no related party transactions that would be required to be disclosed
therein by Item&nbsp;404 of Regulation S-K promulgated under the Act and any such related party transactions described therein
are accurately described in all material respects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
Except (i) as set forth or described in the Pricing Disclosure Package, none of the following events has occurred or exists: (A)
a failure to fulfill the obligations, if any, under the minimum funding standards of Section 302 of the United States Employee
Retirement Income Security Act of 1974, as amended (&ldquo;<B><I>ERISA</I></B>&rdquo;), and the regulations and published interpretations
thereunder with respect to a Plan, determined without regard to any waiver of such obligations or extension of any amortization
period; (B) an audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty
Corporation or any other federal or state governmental agency or any foreign regulatory agency with respect to the employment
or compensation of employees by any of the Company or any of its subsidiaries; or (C) any breach of any contractual obligation,
or any violation of law or applicable qualification standards, with respect to the employment or compensation of employees by
the Company or any of its subsidiaries. Except (i) as set forth or described in the Pricing Disclosure Package or (ii) as would
not have, individually or in the aggregate, a Material Adverse Effect, none of the following events has occurred or is reasonably
likely to occur: (A) an increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal
year of the Company and its subsidiaries compared to the amount of such contributions made in the most recently completed fiscal
year of the Company and its subsidiaries; (B) an increase in the &ldquo;accumulated post-retirement benefit obligations&rdquo;
(within the meaning of Statement of Financial Accounting Standards 106) of the Company and its subsidiaries compared to the amount
of such obligations in the most recently completed fiscal year of the Company and its subsidiaries; (C) any event or condition
giving rise to a liability under Title IV of ERISA; or (D) the filing of a material claim by one or more employees or former employees
of the Company or any of its subsidiaries related to their employment. For purposes of this paragraph, the term &ldquo;Plan&rdquo;
means a plan (within the meaning of Section 3(3) of ERISA) with respect to which the Company or any of its subsidiaries may have
any liability;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with ERISA,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the &ldquo;<B><I>Employee Benefit Laws</I></B>&rdquo;) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator to which the Company or any of its subsidiaries
is a party with respect to the Employee Benefit Laws is pending or, to the knowledge of the Company, threatened;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
There are no contracts, agreements or understandings between the Company or its subsidiaries and any person that would give rise
to a valid claim against the Company or any Underwriter for a brokerage commission, finder&rsquo;s fee or other like payment in
connection with this offering;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
The holders of outstanding shares of the Company&rsquo;s capital stock are not entitled to preemptive or other rights to subscribe
for the Securities that have not been complied with or otherwise effectively waived; none of the outstanding shares of Common
Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase
securities of the Company; there are no persons with registration or other similar rights to have securities of the Company registered
under the Act other than as disclosed in the Pricing Disclosure Package; and there are no Persons with registration or similar
rights that would require any securities of the Company to be included in the Registration Statement or in the offering contemplated
hereby; there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to
purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or
any of its subsidiaries other than those described in the Pricing Disclosure Package; and the description of the Company&rsquo;s
stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, included
in the Pricing Disclosure Package fairly presents the information required to be shown with respect to such plans, arrangements,
options and rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
(i) Neither the Company nor any of its subsidiaries, nor any or their directors, officers or employees, nor, to the Company&rsquo;s
knowledge, any agent, affiliate or representative of the Company or its subsidiaries, is an individual or entity that is, or is
owned or controlled by an individual or entity that is (A) the subject of any sanctions administered or enforced by the U.S. Department
of Treasury&rsquo;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&rsquo;s
Treasury or other relevant sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor (B) located, organized
or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran,
Libya, North Korea, Sudan, Syria or the Crimean region of Ukraine); (ii) neither the Company nor any of its subsidiaries will,
directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other individual or entity (A) to fund or facilitate any activities or business of or with
any individual or entity or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions;
or (B) in any other manner that will result in a violation of Sanctions by any individual or entity (including any individual
or entity participating in the offering, whether as underwriter, advisor, investor or otherwise); (iii) for the past five years,
neither the Company nor any of its subsidiaries has knowingly engaged in, and is not now knowingly engaged in, any dealings or
transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is
or was the subject of Sanctions.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable federal,
state, international, foreign or other laws, regulations or government guidance regarding financial record-keeping and reporting
requirements, including, without limitation, Title 18 US. Code section 1956 and 1957, the Bank Secrecy Act, as amended by Title
III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of
2001 (USA PATRIOT Act), the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering
statutes of jurisdictions where the Company and the subsidiaries conduct business, the applicable rules and regulations thereunder,
and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial
Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative
to the group or organization continues to concur, all as amended, and any Executive order, directive or regulation pursuant to
the authority of any of the foregoing, or any orders or licenses issued thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;),
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
Neither the Company nor any of its subsidiaries, nor any director or officer thereof, nor, to the Company&rsquo;s knowledge, any
agent, employee or affiliate of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly,
that would result in a violation by such Persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the &ldquo;<B><I>FCPA</I></B>&rdquo;), including, without limitation, making use of the mails or any means or instrumentality
of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money,
or other property, gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo;
(as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political
office, in contravention of the FCPA and the Company, its subsidiaries and its affiliates have conducted their businesses in compliance
with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to
continue to ensure, continued compliance therewith;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
The Company and, as applicable, each of its subsidiaries holds all material, and is operating in material compliance with, all
certificates, registrations, franchises, licenses, permits, clearances, approvals, exemptions, and other authorizations issued
by all applicable authorities, including the United States Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;), and
any state, federal or foreign regulatory agencies or bodies required for the conduct of its business as currently conducted (collectively,
&ldquo;<B><I>Permits</I></B>&rdquo;), and all such Permits are in full force and effect; the Company and each of its subsidiaries
have fulfilled and performed all of their material obligations with respect to the Permits, and, to the Company&rsquo;s knowledge,
no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results
in any other material impairment of the rights of the holder of any Permit; to the Company&rsquo;s knowledge, all applications,
notifications, submissions, information, claims, reports and statistics, and other data and conclusions derived therefrom, utilized
as the basis for any and all requests for a Permit from the FDA or any other Governmental Authority relating to the Company and
its subsidiaries, their business and the products of the Company, when submitted the FDA or to such other Governmental Authority,
were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes,
corrections or modification to such applications, submissions, information and data have been submitted to the FDA or such other
Governmental Authority;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
The nonclinical tests, clinical trials and other studies (collectively, &ldquo;<B><I>studies</I></B>&rdquo;) that are described
in, or the results of which are referred to in, the Registration Statement, the Pricing Disclosure Package or the Prospectus were
and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls
designed and approved for such studies and with standard medical and scientific research procedures; each description of the results
of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and
the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise
call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the
Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by
the FDA or from any other U.S. or foreign government or drug regulatory agency, or health care facility Institutional Review Board
(collectively, the &ldquo;<B><I>Regulatory Agencies</I></B>&rdquo;); the Company and its subsidiaries have not received any notice
of, or correspondence from, any Regulatory Agency requiring the termination or suspension of any clinical trials that are described
or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; and the Company and its subsidiaries
have operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory
Agencies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
The Company and each of its subsidiaries and its and their respective directors and officers and, to the Company&rsquo;s knowledge,
its employees and agents (while acting in such capacity) are, and at all times have been, in material compliance with, all healthcare
laws applicable to the Company and each of its subsidiaries or any of its products or activities, including, but not limited to,
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), as amended, the regulations promulgated pursuant
to such laws, and any other state or federal law, accreditation standards, regulation, memorandum, opinion letter, or other issuance
which imposes requirements on the manufacturing, development, testing, labeling, marketing or distribution of pharmaceutical products,
recordkeeping, quality, safety, privacy, security, licensure, accreditation or any other aspect of producing pharmaceutical products(collectively,
&ldquo;<B><I>Healthcare Laws</I></B>&rdquo;). The Company has not received any notification, correspondence or any other written
or oral communication, including notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action (&ldquo;<B><I>Action</I></B>&rdquo;) from any court, arbitrator, third-party, or governmental or regulatory
authority, including, without limitation, the FDA, the Drug Enforcement Administration (&ldquo;<B><I>DEA</I></B>&rdquo;), or the
U.S. Department of Health and Human Services Office of Inspector General, of potential or actual non-compliance by, or liability
of, the Company or any of its subsidiaries under any Healthcare Laws, and to the knowledge of the Company, no such Action is threatened;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
The Company is in compliance with all applicable provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations
of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
The interactive data in eXtensbile Business Reporting Language incorporated by reference in the Registration Statement, the Pricing
Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared
in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
The Company, or any of its subsidiaries, is not a party to and does not have any ongoing reporting obligations pursuant to any
corporate integrity agreements, monitoring agreements, deferred prosecution agreements, consent decrees, settlement orders, or
similar agreements with or imposed by any governmental or regulatory authority;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
Neither the Company, any of its subsidiaries, nor any of their respective employees, officers or directors has been excluded,
suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or is subject
to a governmental inquiry, claim, investigation, proceeding, or other any other Action that could reasonably be expected to result
in debarment, suspension, or exclusion; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the
directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required
by the Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and
in the Pricing Disclosure Package. As of the date of the initial filing of the Registration Statement, there were no outstanding
personal loans made, directly or indirectly, by the Company to any director or executive officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
(i) Except as described in the Pricing Disclosure Package or the Registration Statement, there has been no security breach or
incident, unauthorized access or disclosure, or other compromise of or relating to the Company&rsquo;s or its subsidiaries&rsquo;
information technology and computer systems, networks, hardware, software, data and databases (including the data and information
of their respective customers, employees, suppliers, vendors and any third-party data maintained, processed or stored by the Company
and its subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its subsidiaries), equipment
or technology (collectively, &ldquo;<B><I>IT Systems and Data</I></B>&rdquo;), except for those that have been remedied without
material cost or liability; (ii) neither the Company nor its subsidiaries have been notified of, and have no knowledge of any
event or condition that would reasonably be expected to result in, any security breach or incident, unauthorized access or disclosure
or other compromise to their IT Systems and Data; and (iii) the Company and its subsidiaries, taken as a whole, have implemented
appropriate controls, policies, procedures and technological safeguards to maintain and protect the integrity, continuous operation,
redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required
by applicable regulatory standards. The Company and its subsidiaries are presently in material compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any Governmental Entity, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from
unauthorized use, access, misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not sold,
issued or distributed any shares of Common Stock during the six month period preceding the date hereof, including any sales pursuant
to Rule 144A under, or Regulation D or S of, the Act, other than shares issued pursuant to Company Stock Plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
There are no debt securities or preferred stock issued, or guaranteed by, the Company or any of its subsidiaries that are rated
by a &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is defined in Section 3(a)(62) of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Subject to the terms and conditions herein set forth, the Company agrees to issue and sell to each of the Underwriters, and each
of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a combined purchase price per Share and
Warrant of $0.3581, the number of Shares and Warrants set forth opposite the name of such Underwriter in Schedule I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Upon the authorization by you of the release of the Securities, the several Underwriters propose to offer the Securities for sale
upon the terms and conditions set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
(a) The Securities to be purchased by each Underwriter hereunder, in definitive form, and in such authorized denominations and
registered in such names as William Blair &amp; Company, L.L.C. may request upon at least forty-eight hours&rsquo; prior notice
to the Company shall be delivered by or on behalf of the Company to the Representative, through the facilities of the Depository
Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;), for the account of such Underwriter, against payment by or on behalf of such
Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the account specified by the Company
to the William Blair&nbsp;&amp; Company, L.L.C. at least forty-eight hours in advance. The time and date of such delivery and
payment shall be, with respect to the Securities, 9:30 a.m., New York City time, on April 23, 2019 or such other time and date
as William Blair &amp; Company, L.L.C. and the Company may agree upon in writing. Such time and date for delivery of the Securities
is herein called the &ldquo;<B><I>Time of Delivery</I></B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The documents to be delivered at the Time of Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof,
including the cross-receipt for the Securities and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(l)
hereof, will be delivered at the offices of Latham &amp; Watkins LLP, at 330 North Wabash Avenue, Suite 2800, Chicago, Illinois
60611 (the &ldquo;<B><I>Closing Location</I></B>&rdquo;), and the Securities will be delivered at the office of DTC (or its designated
custodian), all at the Time of Delivery. A meeting will be held at the Closing Location at 4:00 p.m., New York City time, on the
New York Business Day immediately preceding the Time of Delivery, at which meeting the final drafts of the documents to be delivered
pursuant to the preceding sentence will be available for review by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company agrees with each of the Underwriters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act not later
than the Commission&rsquo;s close of business on the second business day following the execution and delivery of this Agreement
or such earlier time as may be required under the Act; to make no further amendment or any supplement to the Registration Statement,
the Basic Prospectus or the Prospectus prior to the Time of Delivery which shall be disapproved by you promptly after reasonable
notice thereof; to advise you, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement
has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies
thereof; to file promptly all other material required to be filed by the Company with the Commission pursuant to Rule 433(d) under
the Act, within the time required by such rule; to file promptly all reports and any definitive proxy or information statements
required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act
subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred
to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Securities; to advise you, promptly
after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending
the use of any Preliminary Prospectus or other prospectus in respect of the Securities, of the suspension of the qualification
of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose,
or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional
information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary
Prospectus or other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal
of such order;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Promptly from time to time to take such action as you may reasonably request to qualify the Securities for offering and sale under
the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales
and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the Securities, provided
that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent
to service of process in any jurisdiction or subject itself to taxation in any jurisdiction in which it is not otherwise subject
to taxation on the date hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement and from time
to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities
as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a)
under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection
with the offering or sale of the Securities and if at such time any event shall have occurred as a result of which the Prospectus
as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or
in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason
it shall be necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document
incorporated by reference in the Prospectus in order to comply with the Act or the Exchange Act, to notify you and upon your request
to file such document and to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written
and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus
which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a
prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the Securities
at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter,
to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented
Prospectus complying with Section&nbsp;10(a)(3) of the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
To make generally available to its securityholders as soon as practicable, but in any event not later than sixteen months after
the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the Company
and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of
the Commission thereunder (including, at the option of the Company, Rule 158);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
During the period beginning from the date hereof and continuing to and including the date 90 days after the date of the Prospectus
(the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;), not to (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase,
make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement
under the Act relating to, any securities of the Company that are substantially similar to the Securities, including but not limited
to any options or warrants to purchase shares of Common Stock or any securities that are convertible into or exchangeable for,
or that represent the right to receive, Common Stock, or any such substantially similar securities, or publicly disclose the intention
to make any offer, sale, pledge, disposition or filing or (ii)&nbsp;enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of the Common Stock, or any such other securities, whether any
such transaction described in clause (i) or (ii)&nbsp;above is to be settled by delivery of Common Stock or such other securities,
in cash or otherwise, without the prior written consent of the Representative (other than (A)&nbsp;the Securities to be sold to
the Underwriters hereunder, (B)&nbsp;the issuance of options, warrants or other equity awards to acquire shares of Common Stock
granted pursuant to the Company Stock Plans that are described in the Prospectus, as such plans may be amended, (C)&nbsp;the issuance
of shares of Common Stock upon the exercise of any such options, warrants or other equity awards to acquire shares of Common Stock
and (D)&nbsp;shares of Common Stock issued upon exercise of outstanding warrants, provided that such warrants have not been amended
since the date hereof to increase the number of such warrants or to decrease the exercise price, exchange price or conversion
price of such warrants or to extend the term of such warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If the Company elects to rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the Commission
in compliance with Rule 462(b) by 10:00 p.m., Washington, D.C. time, on the date of this Agreement, and the Company shall at the
time of filing either pay the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions
for the payment of such fee pursuant to Rule 111(b) under the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
To use the net proceeds received by it from the sale of the Securities pursuant to this Agreement in the manner specified in the
Pricing Prospectus under the caption &ldquo;Use of Proceeds&rdquo;;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
To use its best efforts to list, subject to notice of issuance, the Securities and, when issued, the Warrant Shares on the NYSE
American;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Upon request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&rsquo;s
trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating
the on-line offering of the Securities (the &ldquo;<B><I>License</I></B>&rdquo;); <I>provided, however</I>, that the License shall
be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company represents and agrees that, unless it obtains the prior written consent of the Representative, and each Underwriter
severally represents and agrees that, unless it obtains the prior written consent of the Company and the Representative, it has
not made and will not make any offer relating to the Securities that would constitute an issuer free writing prospectus or that
would otherwise constitute a free writing prospectus required to be filed with the Commission; provided that the prior written
consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in Schedule
II. Any such free writing prospectus consented to by the Company and the Representative is hereinafter referred to as a &ldquo;<B><I>Permitted
Free Writing Prospectus</I></B><I>.</I>&rdquo; The Company represents that it has treated or agrees that it will treat each Permitted
Free Writing Prospectus as an issuer free writing prospectus, and has complied and will comply with the requirements of Rules
164 and 433 of the Rules and Regulations applicable to any Permitted Free Writing Prospectus. The Company represents that it has
satisfied and agrees that it will satisfy the conditions in Rule 433 to avoid a requirement to file with the Commission any electronic
road show.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.(a)
The Company represents and agrees that, without the prior consent of the Representative, it has not made and will not make any
offer relating to the Securities that would constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the
Act, other than any such free writing prospectus the use of which has been consented to by the Representative and which is listed
on Schedule II(a) hereto; each Underwriter represents and agrees that, without the prior consent of the Company and the Representative,
it has not made and will not make any offer relating to the Securities that would constitute a free writing prospectus, other
than any such free writing prospectus the use of which has been consented to by the Company and the Representative is listed on
Schedule II(a) hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing
Prospectus, including timely filing with the Commission or retention where required and legending; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus any event occurred or occurs as
a result of which such Issuer Free Writing Prospectus would conflict with the information in the Registration Statement, the Pricing
Disclosure Package or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company
will give prompt notice thereof to the Representative and, if requested by the Representative, will prepare and furnish without
charge to each Underwriter an Issuer Free Writing Prospectus or other document which will correct such conflict, statement or
omission; provided, however, that this representation and warranty shall not apply to any statements or omissions in an Issuer
Free Writing Prospectus made in reliance upon and in conformity with information furnished in writing to the Company by an Underwriter
through the Representative expressly for use therein, it being understood and agreed that the only such information provided by
any Underwriter through the Representative is that identified as such in Section 9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i)&nbsp;the
fees, disbursements and expenses of the Company&rsquo;s counsel and accountants in connection with the registration of the Securities
under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration
Statement, the Basic Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus and the Prospectus and amendments
and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii)&nbsp;the cost of
printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents (including
any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Securities;
(iii)&nbsp;all expenses in connection with the qualification of the Securities for offering and sale under state securities laws,
including the fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with
the Blue Sky survey; (iv)&nbsp;all fees and expenses in connection with listing the Securities on the NYSE American; (v)&nbsp;if
applicable, the filing fees incident to, and the fees and disbursements of counsel for the Underwriters in connection with, any
required review by FINRA of the terms of the sale of the Securities (such fees not to exceed $25,000); (vi)&nbsp;if applicable,
the costs incidental to the issuance of the Securities, including the costs of preparation, printing and distribution of one or
more versions of the Preliminary Prospectus and the Prospectus for distribution in Canada, in the form of a Canadian &ldquo;wrapper&rdquo;
(including related fees and disbursements of Canadian counsel to the Underwriters; (vii) the cost of preparing stock certificates,
if applicable; (viii)&nbsp;the cost and charges of any transfer agent or registrar; (ix) the costs and expenses of the Company
relating to investor presentations on any &ldquo;road show&rdquo; undertaken in connection with the marketing of the Securities,
including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any
consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers
of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road
show; and (x)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise
specifically provided for in this Section 7. It is understood, however, that, except as provided in this Section 7, Sections 9
and 12 hereof and the engagement letter dated February 13, 2019, between William Blair &amp; Company, L.L.C. and the Company,
the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, transfer taxes on resale of
any of the Securities by them, and any advertising expenses connected with any offers they may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
The obligations of the Underwriters hereunder, as to the Securities to be delivered at the Time of Delivery, shall be subject,
in their discretion, to the condition that all representations and warranties and other statements of the Company herein are,
at and as of the Time of Delivery, true and correct, the condition that the Company shall have performed all of its obligations
hereunder theretofore to be performed, and the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period
prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material
required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the
applicable time period prescribed for such filings by Rule 433; if the Company has elected to rely upon Rule 462(b) under the
Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 p.m., Washington, D.C. time, on the date of this
Agreement; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued
and no proceeding for that purpose shall have been initiated or threatened by the Commission; no stop order suspending or preventing
the use of the Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and
all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Latham &amp; Watkins LLP, counsel for the Underwriters, shall have furnished to you such written opinion or opinions, dated the
Time of Delivery, in form and substance satisfactory to you, with respect to the matters you may reasonably request, and such
counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
(i) The Matt Law Firm, PLLC, counsel for the Company, shall have furnished to you their written opinion and a negative assurance
letter, dated the Time of Delivery, in form and substance satisfactory to you; and (ii) WilmerHale LLP, intellectual property
counsel for the Company, shall have furnished to you their written opinion, dated such Time of Delivery, in form and substance
satisfactory to you;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
On the date of the Prospectus at a time prior to the execution of this Agreement, on the effective date of any post-effective
amendment to the Registration Statement filed subsequent to the date of this Agreement and also at the Time of Delivery, Marcum
LLP shall have furnished to you a comfort letter or letters, dated the respective dates of delivery thereof, in form and substance
satisfactory to the Representative, in form and substance satisfactory to you;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)(i)
Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements
included or incorporated by reference in the Pricing Disclosure Package any loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action,
order or decree, otherwise than as set forth or contemplated in the Pricing Disclosure Package, and (ii)&nbsp;since the respective
dates as of which information is given in the Pricing Disclosure Package there shall not have been any change in the capital stock
or long-term debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change,
in or affecting the properties, business, management, prospects, operations, earnings, assets, liabilities or condition (financial
or otherwise) of the Company and its subsidiaries, otherwise than as set forth or contemplated in the Pricing Disclosure Package,
the effect of which, in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and adverse as to
make it impracticable or inadvisable to proceed with the public offering or the delivery of the Securities being delivered at
the Time of Delivery on the terms and in the manner contemplated in the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
On or after the Applicable Time (i)&nbsp;no downgrading shall have occurred in the rating accorded the Company&rsquo;s securities
by any &ldquo;nationally recognized statistical rating organization,&rdquo; as that term is defined by the Commission for purposes
of Section 3(a)(62) of the Exchange Act, and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance
or review, with possible negative implications, its rating of any of the Company&rsquo;s debt securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
On or after the Applicable Time there shall not have occurred any of the following: (i)&nbsp;a suspension or material limitation
in trading in securities generally on the New York Stock Exchange, NYSE American or on the NASDAQ; (ii)&nbsp;a suspension or material
limitation in trading in the Company&rsquo;s securities on the NYSE American; (iii)&nbsp;a general moratorium on commercial banking
activities declared by either Federal or New York authorities or a material disruption in commercial banking or securities settlement
or clearance services in the United States; (iv)&nbsp;the outbreak or escalation of hostilities involving the United States or
the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis
or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event
specified in clause (iv)&nbsp;or (v)&nbsp;in your judgment makes it impracticable or inadvisable to proceed with the public offering
or the delivery of the Securities being delivered at the Time of Delivery on the terms and in the manner contemplated in the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Securities (and the Warrant Shares underlying the Warrants) to be sold at the Time of Delivery shall have been duly listed,
subject to notice of issuance, on the NYSE American;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company shall, at all times while any Warrants are outstanding, reserve and keep available out of the aggregate of its authorized
but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of such Warrants, the number of Warrant Shares that are issuable and deliverable upon the exercise of the then-outstanding
Warrants from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall have obtained and delivered to the Underwriters executed copies of a lock-up letter from the persons listed
on Schedule III hereto, substantially to the effect set forth in Annex I hereof in form and substance satisfactory to the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company shall have complied with the provisions of Section&nbsp;5(c) hereof with respect to the furnishing of prospectuses
on the New York Business Day next succeeding the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company shall have furnished or caused to be furnished to you at the Time of Delivery a certificate of the Chief Executive
Officer and the Principal Financial Officer of the Company satisfactory to you as to the accuracy of the representations and warranties
of the Company herein at and as of such time, as to the performance by the Company of all of its obligations hereunder to be performed
at or prior to such time, as to the matters set forth in subsections (a), (e), (f)&nbsp;and (h)&nbsp;of this Section&nbsp;8 and
as to such other matters as you may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company will furnish the Representative with any additional opinions, certificates, letters and documents as the Representative
reasonably requests and conformed copies of documents delivered pursuant to this Section 8. The Representative may in its sole
discretion waive on behalf of the Underwriters compliance with any conditions to the obligations of the Underwriters hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
On the date of the Prospectus at a time prior to the execution of this Agreement, on the effective date of any post-effective
amendment to the Registration Statement filed subsequent to the date of this Agreement and also at the Time of Delivery, the Company
shall have furnished or caused to be furnished to you a certificate of the Principal Financial Officer of the Company satisfactory
to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.(a)
The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several,
to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) (i) arise out of or are based upon an untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Disclosure Package
or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus or any &ldquo;issuer information&rdquo;
filed or required to be filed pursuant to Rule 433(d) under the Act, or any road show as defined in Rule 433(h) under the Act
(a &ldquo;<B><I>road show</I></B>&rdquo;), or (ii) arise out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each
Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending
any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case
to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus,
the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus,
in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representative
expressly for use therein, it being understood and agreed that the only such information provided by any Underwriter through the
Representative is that identified as such in Section 9(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Underwriter will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the
Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) (i) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus,
or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any road show or (ii) arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus,
the Pricing Disclosure Package or the Prospectus or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus,
in reliance upon and in conformity with written information furnished to the Company by such Underwriter through the Representative
expressly for use therein, it being understood and agreed that the only such information provided by any Underwriter through the
Representative is the information contained in the fourth and the eleventh through sixteenth paragraphs under the caption &ldquo;Underwriting&rdquo;
in the Preliminary Prospectus and the Prospectus; and will reimburse the Company for any legal or other expenses reasonably incurred
by the Company in connection with investigating or defending any such action or claim as such expenses are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b)&nbsp;above of notice of the commencement of any
action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection,
notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying party shall
not relieve it from any liability which it may have to any indemnified party under such subsection, except to the extent that
the indemnifying party has been materially prejudiced by such failure. In case any such action shall be brought against any indemnified
party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified
party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election
so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for
any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection
with the defense thereof other than reasonable costs of investigation; provided, however, that if, in the sole judgment of the
Representative, it is advisable for the Underwriters to be represented as a group by separate counsel, the Representative shall
have the right to employ a single counsel (in addition to local counsel) to represent the Representative and all Underwriters
that may be subject to liability arising from any claim in respect of which indemnity may be sought by the Underwriters under
subsection (a) above in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying
party or parties and reimbursed to the Underwriters as incurred. No indemnifying party shall, without the written consent of the
indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending
or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the
indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes
an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not
include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.
Notwithstanding the foregoing, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel pursuant to this Section 9(c), such indemnifying party agrees that it shall
be liable for any settlement effected without its written consent if (i) such settlement is entered into more than 45 days after
receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed such indemnified
party in accordance with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If the indemnification provided for in this Section&nbsp;9 is unavailable to or insufficient to hold harmless an indemnified party
under subsection (a)&nbsp;or (b)&nbsp;above in respect of any losses, claims, damages or liabilities (or actions in respect thereof)
referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as
a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to
reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the
Securities. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law or if
the indemnified party failed to give the notice required under subsection (c)&nbsp;above, then each indemnifying party shall contribute
to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements
or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other
shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received
by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth
in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (d)&nbsp;were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable
by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to
above in this subsection (d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection
(d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Securities
underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations in this subsection
(d)&nbsp;to contribute are several in proportion to their respective underwriting obligations and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The obligations of the Company under this Section&nbsp;9 shall be in addition to any liability which the Company may otherwise
have and shall extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning
of the Act and each affiliate of any Underwriter within the meaning of Rule 405 under the Act, including, without limitation,
the officers, directors, partners and members of each such Underwriter and its broker-dealer affiliates; and the obligations of
the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise
have and shall extend, upon the same terms and conditions, to each officer and director of the Company and to each person, if
any, who controls the Company within the meaning of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.(a)
If any Underwriter shall default in its obligation to purchase the Securities which it has agreed to purchase hereunder at the
Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Securities on
the terms contained herein. If within thirty-six hours after such default by any Underwriter you do not arrange for the purchase
of such Securities, then the Company shall be entitled to a further period of thirty-six hours within which to procure another
party or other parties satisfactory to you to purchase such Securities on such terms. In the event that, within the respective
prescribed periods, you notify the Company that you have so arranged for the purchase of such Securities, or the Company notifies
you that it has so arranged for the purchase of such Securities, you or the Company shall have the right to postpone the Time
of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the
Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any
amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary.
The term &ldquo;Underwriter&rdquo; as used in this Agreement shall include any person substituted under this Section 10 with like
effect as if such person had originally been a party to this Agreement with respect to such Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by
you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Securities which remains unpurchased
does not exceed one eleventh of the aggregate number of all the Securities to be purchased at the Time of Delivery, then the Company
shall have the right to require each non-defaulting Underwriter to purchase the number of shares which such Underwriter agreed
to purchase hereunder at the Time of Delivery and, in addition, to require each non-defaulting Underwriter to purchase its pro
rata share (based on the number of Securities which such Underwriter agreed to purchase hereunder) of the Securities of such defaulting
Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter
from liability for its default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by
you and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Securities which remains unpurchased
exceeds one eleventh of the aggregate number of all the Securities to be purchased at the Time of Delivery, or if the Company
shall not exercise the right described in subsection (b)&nbsp;above to require non-defaulting Underwriters to purchase Securities
of a defaulting Underwriter or Underwriters, then this Agreement shall thereupon terminate, without liability on the part of any
non-defaulting Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided
in Section&nbsp;7 hereof and the indemnity and contribution agreements in Section&nbsp;9 hereof; but nothing herein shall relieve
a defaulting Underwriter from liability for its default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
The respective indemnities, agreements, representations, warranties and other statements of the Company and the several Underwriters,
as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full
force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter
or any controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the Company,
and shall survive delivery of and payment for the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
If this Agreement shall be terminated pursuant to Section&nbsp;10 hereof, the Company shall not then be under any liability to
any defaulting Underwriter; but, if for any other reason, any Securities are not delivered by or on behalf of the Company as provided
herein, the Company will reimburse the Underwriters through you for all out of pocket expenses, including fees and disbursements
of counsel, reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Securities
not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7
and 9 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to act
and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent
by mail or facsimile transmission to William Blair &amp; Company, L.L.C., 150 North Riverside Plaza, Chicago, IL 60606, Attention:
General Counsel, Facsimile: (312) 551-4646; and if to the Company shall be delivered or sent by mail or facsimile transmission
to the address of the Company set forth on the cover of the Registration Statement, Attention: Principal Financial Officer (with
copies to those parties specified thereon). Any such statements, requests, notices or agreements shall take effect upon receipt
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26, 2001)),
the underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will
allow the underwriters to properly identify their respective clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided
in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter,
and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right
under or by virtue of this Agreement. No purchaser of any of the Securities from any Underwriter shall be deemed a successor or
assign by reason merely of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
Time shall be of the essence of this Agreement. As used herein, the term &ldquo;business day&rdquo; shall mean any day when the
Commission&rsquo;s office in Washington, D.C. is open for business and &ldquo;New York Business Day&rdquo; shall mean each Monday,
Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized
or obligated by law or executive order to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
The Company acknowledges and agrees that (i)&nbsp;the purchase and sale of the Securities pursuant to this Agreement is an arm&rsquo;s-length
commercial transaction between the Company, on the one hand, and the several Underwriters, on the other, (ii)&nbsp;in connection
therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent
or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company
with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has
advised or is currently advising the Company on other matters) or any other obligation to the Company except the obligations expressly
set forth in this Agreement and (iv)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed
appropriate. The Company agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of
any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process
leading thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
The Company acknowledges that the Underwriters&rsquo; research analysts and research departments are required to be independent
from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such
Underwriters&rsquo; research analysts may hold views and make statements or investment recommendations and/or publish research
reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions.
The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the
Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent
research analysts and research departments may be different from or inconsistent with the views or advice communicated to the
Company by such Underwriters&rsquo; investment banking divisions. The Company acknowledges that each of the Underwriters is a
full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for
its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies
that may be the subject of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters,
or any of them, with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<B>THIS AGREEMENT AND ANY MATTERS RELATED TO THIS TRANSACTION SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN
THE LAWS OF THE STATE OF NEW YORK. The Company agrees that any suit or proceeding arising in respect of this agreement or your
engagement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not
have subject matter jurisdiction, in any state court located in The City and County of New&nbsp;York and the Company agrees to
submit to the jurisdiction of, and to venue in, such courts. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be
deemed to be an original, but all such counterparts shall together constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any persons the U.S. federal and state
income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and
other tax analyses) provided to the Company relating to that treatment and structure, without the Underwriters imposing any limitation
of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing
sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, &ldquo;tax
structure&rdquo; is limited to any facts that may be relevant to that treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
If any term or other provision of this Agreement shall be held invalid, illegal or unenforceable, the validity, legality or enforceability
of the other provisions of this Agreement shall not be affected thereby, and there shall be deemed substituted for the provision
at issue a valid, legal and enforceable provision as similar as possible to the provision at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
Except as otherwise expressly provided herein, the provisions of this Agreement may be amended or waived at any time only by the
written agreement of the parties hereto. Any waiver, permit, consent or approval of any kind or character on the part of any such
holders of any provision or condition of this Agreement must be made in writing and shall be effective only to the extent specifically
set forth in writing. The failure of any party hereto to enforce at any time any provision of this Agreement shall not be construed
to be a waiver of such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of any
party thereafter to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to constitute
a waiver of any other or subsequent breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding, please sign and return to us, and upon the acceptance hereof by you, on
behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement between each of
the Underwriters and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 36%; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
        Sandesh Seth</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accepted
as of the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WILLIAM
BLAIR &amp; COMPANY, L.L.C.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
severally on behalf of itself and the several Underwriters named in Schedule I hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WILLIAM BLAIR &amp; COMPANY, L.L.C.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1.5pt solid">/s/ Steve Maletzky</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="font-size: 10pt; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Maletzky</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner and
    Managing</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director, ECM</Font></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
I </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> Number&nbsp;of<BR> Shares<BR> to be<BR> Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Underlying Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -12pt; padding-left: 12pt">William Blair &amp; Company, L.L.C.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">37,293,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">37,293,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">JonesTrading Institutional Services LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,328</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; padding-bottom: 1.5pt">Maxim Group LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2,783,328</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2,783,328</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">42,860,000</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">42,860,000</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
II </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
General Use Issuer Free Writing Prospectuses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Additional Documents Incorporated by Reference:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Information other than the Pricing Prospectus that comprise the Pricing Disclosure Package:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined initial public offering price per Share and accompanying Warrant is $0.385</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of Shares purchased by the Underwriters is 42,860,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of Warrants purchased by the Underwriters is 42,860,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price per Warrant is $0.50.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
III </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 30%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid"><B>Name</B></P></TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark S. Berger</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anil Kapur</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale L. Ludwig</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Laughlin</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Lock-Up Letter</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___,
2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
Blair &amp; Company, L.L.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
representative of the underwriters named in Schedule I to the Underwriting Agreement referred to below</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
William Blair&nbsp;&amp; Company, L.L.C.<BR>
150 North Riverside Plaza<BR>
Chicago, IL 60606</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sirs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an inducement to the underwriters (the <B><I>&ldquo;Underwriters&rdquo;</I></B>) to execute an underwriting agreement (the <B><I>&ldquo;Underwriting
Agreement&rdquo;</I></B>) providing for a public offering (the <B><I>&ldquo;Offering&rdquo;</I></B>) of common stock (the <B><I>&ldquo;Common
Stock&rdquo;</I></B>), of Actinium Pharmaceuticals, Inc., a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), the
undersigned hereby agrees that without, in each case, the prior written consent of William Blair &amp; Company, L.L.C. (the &ldquo;<B><I>Representative</I></B>&rdquo;)
during the period specified in the second succeeding paragraph (the <B><I>&ldquo;Lock-Up Period&rdquo;</I></B>), the undersigned
(or any affiliate of the undersigned or any person in privity with the undersigned or any affiliate of the undersigned) will not:
(1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any securities convertible into, exercisable or exchangeable for or
that represent the right to receive Common Stock (including without limitation, Common Stock which may be deemed to be beneficially
owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission (the <B><I>&ldquo;SEC&rdquo;</I></B>)
and securities which may be issued upon exercise of a stock option or warrant), whether now owned or hereafter acquired (the <B><I>&ldquo;Undersigned&rsquo;s
Securities&rdquo;</I></B>); (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic
consequences of ownership of the Undersigned&rsquo;s Securities, whether any such transaction described in clause (1) above or
this clause (2) is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; (3) make any demand
for or exercise any right with respect to, the registration of any Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock; or (4) publicly disclose the intention to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees that the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction
that is designed to or that reasonably could be expected to lead to or result in a sale or disposition of the Undersigned&rsquo;s
Securities even if such Undersigned&rsquo;s Securities would be disposed of by someone other than the undersigned. Such prohibited
hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including
without limitation any put or call option) with respect to any of the Undersigned&rsquo;s Securities or with respect to any security
that includes, relates to, or derives any significant part of its value from such Undersigned&rsquo;s Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Lock-Up Period will commence on the date of this lock-up agreement (this <B><I>&ldquo;Lock-Up Agreement&rdquo;</I></B>) and continue
and include the date 90 days after the date of the final prospectus used to sell Common Stock in the Offering pursuant to the
Underwriting Agreement relating to the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is an officer or director of the Company, (i) the Representative agrees that, at least three business days before
the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock,
the Representative will notify the Company of the impending release or waiver, and (ii) the Company will announce the impending
release or waiver by issuing a press release through a major news service at least two business days before the effective date
of the release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall
only be effective two business days after the publication date of such press release. The provisions of this paragraph will not
apply if both (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has
agreed in writing to be bound by the same terms described in this letter that are applicable to the transferor, to the extent
and for the duration that such terms remain in effect at the time of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the undersigned may transfer the Undersigned&rsquo;s Securities: (i) as a <I>bona fide</I> gift or gifts; (ii)
to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned; (iii) if the undersigned
is a corporation, partnership, limited liability company, trust or other business entity, (a) to another corporation, partnership,
limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated
under the Securities Act of 1933, as amended) of the undersigned or (b) in distributions of shares of Common Stock or any security
convertible into or exercisable for Common Stock to limited partners, limited liability company members or stockholders of the
undersigned; (iv) if the undersigned is a trust, to the beneficiary of such trust; or (v) by testate succession or intestate succession;
<I>provided,</I> in the case of clauses (i)-(v), that (x) such transfer shall not involve a disposition for value, (y) the transferee
agrees in writing with the Underwriters to be bound by the terms of this Lock-Up Agreement and (z) no filing by any party under
Section 16(a) of the Securities Exchange Act of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;</I></B>), shall be required
or shall be made voluntarily in connection with such transfer. For purposes of this Lock-Up Agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the foregoing restrictions shall not apply to: (i)&nbsp;the undersigned&rsquo;s exercise of equity-based awards granted
pursuant to the Company&rsquo;s equity incentive plans in place as of the date of this Lock-Up Agreement; <I>provided</I>, that
(a) such restrictions shall apply to any of the Undersigned&rsquo;s Securities issued upon such exercise and (b) that if any filing
is required under Section 16(a) of the Exchange Act in connection with such exercise, such filing shall include a statement to
the effect that such filing is the result of the exercise of equity-based securities pursuant to the Company&rsquo;s equity incentive
plans; or (ii)&nbsp;the establishment of any contract, instruction or plan (a <B><I>&ldquo;Plan&rdquo;</I></B>) that satisfies
all of the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act; <I>provided</I>, that no sales of the Undersigned&rsquo;s
Securities shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period, and such a Plan may only be established
if no public announcement of the establishment or existence thereof and no filing with the SEC or other regulatory authority in
respect thereof or transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall
be required, and no such announcement or filing is made voluntarily, by the undersigned, the Company or any other person, prior
to the expiration of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
furtherance of the foregoing, the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer
of shares of Common Stock if such transfer would constitute a violation or breach of this Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement
and that upon request, the undersigned will execute any additional documents necessary to ensure the validity or enforcement of
this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall
be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the undersigned shall be released from all obligations under this Lock-Up Agreement if (i)&nbsp;the
Company notifies the Underwriters in writing that it does not intend to proceed with the Offering, (ii) the Representative notifies
the Company in writing that they have determined not to proceed with the Offering, (iii) the Underwriting Agreement (other than
the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common
Stock to be sold thereunder or (iv) the Underwriting Agreement does not become effective by April 30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Offering in
reliance upon this Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed Name of Holder</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed Name of Person Signing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(if signing as a custodian, trustee or on behalf of an entity, please indicate capacity of person signing)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: &nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Number: [&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: April 23, 2019</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a company organized under the laws of Delaware (the &ldquo;<U>Company</U>&rdquo;), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged<FONT STYLE="text-transform: uppercase">,
[HOLDER]</FONT>, the registered holder hereof or its permitted assigns (the &ldquo;<U>Holder</U>&rdquo;), is entitled, subject
to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time
or times on or after April 23, 2019 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;), but not after 11:59 p.m., New York time,
on the Expiration Date (as defined below), ______________ &nbsp;fully paid non-assessable shares of Common Stock (as defined below),
subject to adjustment as provided herein (the &ldquo;<U>Warrant Shares</U>&rdquo;). Except as otherwise defined herein, capitalized
terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or
replacement hereof, this &ldquo;<U>Warrant</U>&rdquo;), shall have the meanings set forth in Section 1. This Warrant is one of
the Warrants to purchase Common Stock (the &ldquo;<U>Warrants</U>&rdquo;) issued pursuant to (i) that certain Underwriting Agreement,
dated as of April 18, 2019 by and between the William Blair &amp; Company, L.L.C., (ii) the Company&rsquo;s Registration Statement
on Form S-3 (as defined below) and (iii) the Company&rsquo;s prospectus supplement dated as of April 18, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined
elsewhere in this Warrant, the following terms shall have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the agreement, dated as of April 18, 2019, between the Company and William Blair &amp; Company, L.L.C.,
as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<U>Expiration
Date</U>&quot; means the date five (5) years after the Initial Exercise Date or, if such date falls on a day other than a Business
Day or on which trading does not take place on the principal Trading Market (a &quot;<U>Holiday</U>&quot;), the next day that
is not a Holiday. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-3, as amended (File No. 333-216748).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of
2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121, Attention: Justeene Blankenship, a phone number of (801) 274-1088,
and an e-mail address of jb@actionstocktransfer.com, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise; No Settlement in Cash</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Subject to the terms and conditions hereof, exercise of the purchase rights represented by this Warrant may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Expiration Date by
delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto (&ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; solely in respect of the circumstance
set forth in Section 2(c), and without limiting the right to receive cash payments under the liquidated damages provision of Section
2(d)(i) and the buy-in provision of Section 2(d)(iv), in no event will the Company be required to net cash settle a warrant exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The exercise price per share of the Common Stock under this Warrant shall be $0.50, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice
of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify; text-indent: -81pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify; text-indent: -81pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical
delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is the earlier of (i) the earlier of (A) two (2) Trading Days after the delivery to the Company
of the Notice of Exercise, and (B) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company, and (ii)
the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
(such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be
deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
has been exercised, irrespective of the date of delivery of the Warrant Shares; provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company
fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares
subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of the
Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a
new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new
Warrant shall in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. &nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to a Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery
of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of
any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event
exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.
Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with
the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions payable in shares of Common Stock on shares of its Common Stock or any other Common Stock
Equivalents or preferred stock or other equity securities of the Company (which, for avoidance of doubt, shall not include any
shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock
into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into
a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the
Company, then the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding treasury shares, of the Company) outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionally adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.
Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision, combination or re-classification.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) &nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a
record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to
such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such
Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder's right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Notice
to Holder</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or e-mail a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. To the
extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, the Company effects (i) any merger or consolidation of the
Company with or into another Person (an &ldquo;<U>Acquisition</U>&rdquo;), (ii) any sale of all or substantially all of its assets
in one or a series of related transactions (an &ldquo;<U>Asset Sale</U>&rdquo;), (iii) any tender offer or exchange offer (whether
by the Company or another Person) pursuant to which holders of Common Stock are permitted to tender or exchange their shares for
other securities, cash or property (a &ldquo;<U>Tender Offer</U>&rdquo;), (iv) any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property or (v) any consummation of a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) with another Person or group of Persons (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, this Warrant shall remain outstanding according to its terms except that, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), at the option of the Holder, the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable upon or as a result of such Fundamental Transaction by a Holder of the number of shares of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on
the exercise of this Warrant). If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding the foregoing, in the event the Fundamental
Transaction is in the form of an Acquisition, Asset Sale or Tender Offer, and the consideration payable with respect to the holders
of Common Stock of the Company is solely paid in cash (a &ldquo;<U>Cash Transaction</U>&rdquo;), then, if the Holder does not
exercise this Warrant prior to the consummation of the Cash Transaction, this Warrant shall automatically be exercised pursuant
to Section 2(c) hereof (at the price under Section 2(c) selected by the Holder), without any action by the Holder immediately
prior to the consummation of such Cash Transaction; <U>provided</U>, <U>however</U>, that any exercise of this Warrant in accordance
with this sentence is subject to the provisions of Section 2(e) herein. The Company shall provide the Holder with written notice
of the Cash Transaction (together with such reasonable information as the Holder may request in connection with such contemplated
Cash Transaction giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing
of the proposed Cash Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under
this Warrant in accordance with the provisions of this Section 3(f) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall,
at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such
Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Right
to Call</U>. The Company may call this Warrant for redemption upon written notice (&ldquo;<U>Call Notice</U>&rdquo;) to all purchasers
of the Warrants pursuant to the transactions contemplated by the Underwriting Agreement if the closing price of the Common Stock
exceeds $1.50 (as adjusted for reverse and forward stock splits, recapitalizations and similar transactions following the Initial
Exercise date) for ten (10) consecutive Trading Days (&ldquo;<U>Measurement Period</U>&rdquo;), as reported by Bloomberg, provided
that there is an effective registration statement covering the issuance of the Warrant Shares on each day during the Measurement
Period and during the Exercise Period. Such Call Notice shall be delivered within one Trading Day of the end of the Measurement
Period. In the thirty (30) calendar days following the date the date of delivery of the Call Notice in accordance with Section
3 hereof (the &ldquo;<U>Exercise Period</U>&rdquo; and the 30<SUP>th</SUP> calendar day following the delivery of the Call Notice,
the &ldquo;<U>Call Date</U>&rdquo;), the Holder may choose to exercise this Warrant or a portion of the Warrant and the Company
covenants and agrees that the Company shall honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice.
The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than all of the Warrants shall
first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining Warrant Shares available
for purchase under this Warrant. Any Warrant Shares subject to a Call Notice that are not exercised by 6:30 p.m. (New York City
time) on the last day of the Exercise Period will be redeemed by the Company at $0.001 per share; <U>provided</U>, <U>however</U>,
that the Company shall have no right of redemption on any Warrant Shares subject to a Call Notice if the issuance of such Warrant
Shares upon an exercise by the Holder would cause a breach of the Beneficial Ownership Limitation. Notwithstanding anything to
the contrary set forth in this Warrant, the Company may not deliver a Call Notice or require the cancellation of this Warrant
(and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the
Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise delivered by 6:30 p.m. (New York
City time) on the Call Date, and (2) a registration statement shall be effective as to all Warrant Shares and the prospectus thereunder
available for use by the Company for the sale of all such Warrant Shares to the Holder, and (3) the Common Stock shall be listed
or quoted for trading on the Trading Market, and (4) there is a sufficient number of authorized shares of Common Stock for issuance
of all Warrant Shares, and (5) the issuance of all Warrant Shares subject to a Call Notice shall not cause a breach of any provision
of Section 2(e) herein. The Company&rsquo;s right to call the Warrants under this Section 3(g) shall be exercised ratably among
the Holders based on each Holder&rsquo;s initial purchase of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder
delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon any exercise under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will
take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) &nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder
does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any notices, consents, waivers or other document or communications required or permitted to be given or delivered under the terms
of this Warrant, including, without limitation, any Notice of Exercise, must be in writing and will be deemed to have been delivered:
(i) upon receipt, if delivered personally; (ii) when sent, if sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party); (iii) when sent, if sent by e-mail (provided that such sent
e-mail is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically
generated message from the recipient&rsquo;s e-mail server that such e-mail could not be delivered to such recipient) and (iv)
if sent by overnight courier service, one (1) Trading Day after deposit with an overnight courier service with next day delivery
specified, in each case, properly addressed to the party to receive the same. If notice is given by facsimile or email, a copy
of such notice shall be dispatched no later than the next business day by first class mail, postage prepaid. The addresses, facsimile
numbers and e-mail addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Principal Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
soloughlin@actiniumpharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to a Holder, to its address, facsimile number or e-mail address set forth herein or on the books and records of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or,
in each of the above instances, to such other address, facsimile number or e-mail address and/or to the attention of such other
Person as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness
of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the sender&rsquo;s facsimile machine containing the time, date and recipient facsimile
number or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from an overnight courier service in accordance with clause (i), (ii) or (iv) above, respectively. A copy of the e-mail
transmission containing the time, date and recipient e- mail address shall be rebuttable evidence of receipt by e-mail in accordance
with clause (iii) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) &nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) &nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) &nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder or the beneficial owner of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) &nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ACTINIUM
    &nbsp;PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
NOTICE OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ACTINIUM
    PHARMACEUTICALS, INC.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Investing Entity:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="width: 54%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 75%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 75%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
ASSIGNMENT FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-bottom: 1.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
_______________ __, ______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature:__________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>f8k041819ex4-1_actinium.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: [&nbsp;&nbsp;&nbsp;  ]</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Number: [  &nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: April 23, 2019</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a company organized under the laws of Delaware (the &ldquo;<U>Company</U>&rdquo;), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged<FONT STYLE="text-transform: uppercase">,
[HOLDER]</FONT>, the registered holder hereof or its permitted assigns (the &ldquo;<U>Holder</U>&rdquo;), is entitled, subject
to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time
or times on or after April 23, 2019 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;), but not after 11:59 p.m., New York time,
on the Expiration Date (as defined below), ______________ fully paid non-assessable shares of Common Stock (as defined below),
subject to adjustment as provided herein (the &ldquo;<U>Warrant Shares</U>&rdquo;). Except as otherwise defined herein, capitalized
terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or
replacement hereof, this &ldquo;<U>Warrant</U>&rdquo;), shall have the meanings set forth in Section 1. This Warrant is one of
the Warrants to purchase Common Stock (the &ldquo;<U>Warrants</U>&rdquo;) issued pursuant to (i) that certain Underwriting Agreement,
dated as of April 18, 2019 by and between the William Blair &amp; Company, L.L.C., (ii) the Company&rsquo;s Registration Statement
on Form S-3 (as defined below) and (iii) the Company&rsquo;s prospectus supplement dated as of April 18, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms shall have the meanings
indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the agreement, dated as of April 18, 2019, between the Company and William Blair &amp; Company, L.L.C.,
as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Expiration
Date</U>&rdquo; means the date five (5) years after the Initial Exercise Date or, if such date falls on a day other than a Business
Day or on which trading does not take place on the principal Trading Market (a &ldquo;<U>Holiday</U>&rdquo;), the next day that
is not a Holiday. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-3, as amended (File No. 333-216748).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of
2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121, Attention: Justeene Blankenship, a phone number of (801) 274-1088,
and an e-mail address of jb@actionstocktransfer.com, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise; No Settlement in Cash</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Subject to the terms and conditions hereof, exercise of the purchase rights represented by this Warrant
may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Expiration Date
by delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto (&ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; solely in respect of the circumstance
set forth in Section 2(c), and without limiting the right to receive cash payments under the liquidated damages provision of Section
2(d)(i) and the buy-in provision of Section 2(d)(iv), in no event will the Company be required to net cash settle a warrant exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be $0.50, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice
of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 153pt; text-align: justify; text-indent: -81pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise,
and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i) the earlier of (A) two (2) Trading Days after the
delivery to the Company of the Notice of Exercise, and (B) one (1) Trading Day after delivery of the aggregate Exercise Price
to the Company, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to
which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares; provided that payment of the
aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.
If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date
of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of the Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to a Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and the Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or,
upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions payable in shares of Common Stock on shares of its Common Stock or any other Common
Stock Equivalents or preferred stock or other equity securities of the Company (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common
Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of
the Company, then the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding treasury shares, of the Company) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionally adjusted such that the aggregate Exercise Price of this Warrant shall remain
unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)   &nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)   &nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Notice to Holder</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by facsimile or e-mail a notice setting forth the Exercise Price after such adjustment and any
resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)   &nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, the Company effects (i) any merger or consolidation of the
Company with or into another Person (an &ldquo;<U>Acquisition</U>&rdquo;), (ii) any sale of all or substantially all of its assets
in one or a series of related transactions (an &ldquo;<U>Asset Sale</U>&rdquo;), (iii) any tender offer or exchange offer (whether
by the Company or another Person) pursuant to which holders of Common Stock are permitted to tender or exchange their shares for
other securities, cash or property (a &ldquo;<U>Tender Offer</U>&rdquo;), (iv) any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property or (v) any consummation of a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) with another Person or group of Persons (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, this Warrant shall remain outstanding according to its terms except that, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), at the option of the Holder, the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable upon or as a result of such Fundamental Transaction by a Holder of the number of shares of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on
the exercise of this Warrant). If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding the foregoing, in the event the Fundamental
Transaction is in the form of an Acquisition, Asset Sale or Tender Offer, and the consideration payable with respect to the holders
of Common Stock of the Company is solely paid in cash (a &ldquo;<U>Cash Transaction</U>"), then, if the Holder does not
exercise this Warrant prior to the consummation of the Cash Transaction, this Warrant shall automatically be exercised pursuant
to Section 2(c) hereof (at the price under Section 2(c) selected by the Holder), without any action by the Holder immediately
prior to the consummation of such Cash Transaction; <U>provided</U>, <U>however</U>, that any exercise of this Warrant in accordance
with this sentence is subject to the provisions of Section 2(e) herein. The Company shall provide the Holder with written notice
of the Cash Transaction (together with such reasonable information as the Holder may request in connection with such contemplated
Cash Transaction giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing
of the proposed Cash Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under
this Warrant in accordance with the provisions of this Section 3(f) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall,
at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such
Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)   &nbsp;<U>Right
to Call</U>. The Company may call this Warrant for redemption upon written notice (&ldquo;<U>Call Notice</U>&rdquo;) to all purchasers
of the Warrants pursuant to the transactions contemplated by the Underwriting Agreement if the closing price of the Common Stock
exceeds $1.50 (as adjusted for reverse and forward stock splits, recapitalizations and similar transactions following the Initial
Exercise date) for ten (10) consecutive Trading Days (&ldquo;<U>Measurement Period</U>&rdquo;), as reported by Bloomberg, provided
that there is an effective registration statement covering the issuance of the Warrant Shares on each day during the Measurement
Period and during the Exercise Period. Such Call Notice shall be delivered within one Trading Day of the end of the Measurement
Period. In the thirty (30) calendar days following the date the date of delivery of the Call Notice in accordance with Section
3 hereof (the &ldquo;<U>Exercise Period</U>&rdquo; and the 30<SUP>th</SUP> calendar day following the delivery of the Call Notice,
the &ldquo;<U>Call Date</U>&rdquo;), the Holder may choose to exercise this Warrant or a portion of the Warrant and the Company
covenants and agrees that the Company shall honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice.
The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than all of the Warrants shall
first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining Warrant Shares available
for purchase under this Warrant. Any Warrant Shares subject to a Call Notice that are not exercised by 6:30 p.m. (New York City
time) on the last day of the Exercise Period will be redeemed by the Company at $0.001 per share; <U>provided</U>, <U>however</U>,
that the Company shall have no right of redemption on any Warrant Shares subject to a Call Notice if the issuance of such Warrant
Shares upon an exercise by the Holder would cause a breach of the Beneficial Ownership Limitation. Notwithstanding anything to
the contrary set forth in this Warrant, the Company may not deliver a Call Notice or require the cancellation of this Warrant
(and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the
Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise delivered by 6:30 p.m. (New York
City time) on the Call Date, and (2) a registration statement shall be effective as to all Warrant Shares and the prospectus thereunder
available for use by the Company for the sale of all such Warrant Shares to the Holder, and (3) the Common Stock shall be listed
or quoted for trading on the Trading Market, and (4) there is a sufficient number of authorized shares of Common Stock for issuance
of all Warrant Shares, and (5) the issuance of all Warrant Shares subject to a Call Notice shall not cause a breach of any provision
of Section 2(e) herein. The Company&rsquo;s right to call the Warrants under this Section 3(g) shall be exercised ratably among
the Holders based on each Holder&rsquo;s initial purchase of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading
Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant
issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon any exercise under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will
take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notices, consents, waivers or other document or communications required or permitted to be given or delivered
under the terms of this Warrant, including, without limitation, any Notice of Exercise, must be in writing and will be deemed
to have been delivered: (i) upon receipt, if delivered personally; (ii) when sent, if sent by facsimile (provided confirmation
of transmission is mechanically or electronically generated and kept on file by the sending party); (iii) when sent, if sent by
e-mail (provided that such sent e-mail is kept on file (whether electronically or otherwise) by the sending party and the sending
party does not receive an automatically generated message from the recipient&rsquo;s e-mail server that such e-mail could not
be delivered to such recipient) and (iv) if sent by overnight courier service, one (1) Trading Day after deposit with an overnight
courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. If notice
is given by facsimile or email, a copy of such notice shall be dispatched no later than the next business day by first class mail,
postage prepaid. The addresses, facsimile numbers and e-mail addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Principal Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
soloughlin@actiniumpharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to a Holder, to its address, facsimile number or e-mail address set forth herein or on the books and records of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or,
in each of the above instances, to such other address, facsimile number or e-mail address and/or to the attention of such other
Person as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness
of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the sender&rsquo;s facsimile machine containing the time, date and recipient facsimile
number or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from an overnight courier service in accordance with clause (i), (ii) or (iv) above, respectively. A copy of the e-mail
transmission containing the time, date and recipient e- mail address shall be rebuttable evidence of receipt by e-mail in accordance
with clause (iii) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
NOTICE OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ACTINIUM
    PHARMACEUTICALS, INC.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Investing Entity:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1.8in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1.8in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WARRANT
ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-bottom: 1.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
_______________ __, ______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature:__________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-top: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>f8k041819ex5-1_actinium.htm
<DESCRIPTION>OPINION OF THE MATT LAW FIRM, PLLC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: right">April 18, 2019</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">275 Madison Avenue, 7th Floor</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">New York, New York 10016</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You have requested our opinion,
as special counsel to Actinium Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), with respect to
certain matters in connection with the issuance and sale by the Company <FONT STYLE="font-size: 10pt">of </FONT><FONT STYLE="background-color: white">an
aggregate of 42,860,000 shares (the <B>&ldquo;Shares&rdquo;</B>), of common stock, par value $0.001 per share (the <B>&ldquo;Common
Stock&rdquo;</B>) of the Company, plus warrants (the <B>&ldquo;Warrants&rdquo;</B>) to purchase an additional 42,860,000 shares
of the Company&rsquo;s Common Stock (the <B>&ldquo;Warrant Shares&rdquo;</B>) pursuant to the Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;), dated April 18, 2019, by and between the Company and William Blair &amp; Company, L.L.C., as representative
of the Underwriters named therein, and as contemplated in the Registration Statement</FONT> on Form S-3 (No. 333-216748) (the &ldquo;<B>Registration
Statement</B>&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities
Act of 1933 (the &ldquo;<B>Act</B>&rdquo;), the prospectus included within the Registration Statement dated October 24, 2017 (the
&ldquo;<B>Base Prospectus</B>&rdquo;), and the prospectus supplement dated April 18, 2019, filed with the Commission pursuant to
Rule 424(b) of the Rules and Regulations of the Act (the <B>&ldquo;Prospectus Supplement</B>&rdquo;). The Base Prospectus and Prospectus
Supplement are collectively referred to as the &ldquo;<B>Prospectus</B>.&rdquo; The Securities are to be distributed or sold, as
applicable, by the Company as described in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to our opinion letter
dated October 3, 2017 and included as Exhibit 5.1 to the Registration Statement. We are delivering this supplemental opinion letter
in connection with the Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have examined and relied
upon the Registration Statement and the Prospectus, the Company&rsquo;s Certificate of Incorporation and By-laws, as currently
in effect, and the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other
instruments as we have deemed relevant in connection with this opinion. We have assumed the genuineness and authenticity of all
documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, and the accuracy,
completeness and authenticity of certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are licensed to practice
in the State of New York. This opinion letter is limited to New York law, the Delaware General Corporation Law and applicable federal
law of the United States. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation
relating to securities or to the sale or issuance thereof. Pertinent to our opinion regarding the Warrant Shares to be sold upon
exercise of the Warrants after the date hereof, we express no opinion to the extent that, notwithstanding its current reservation
of shares of Common Stock, future issuances by the Company of securities, including the Warrant Shares, and antidilution adjustments
to outstanding securities, including the Warrants, may cause the Warrants to be exercisable for more shares of Common Stock than
the number of shares of Common Stock which then are authorized but unissued.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">April 18, 2019</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the basis of the foregoing,
and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that (a) on the date of this letter
<FONT STYLE="background-color: white">the Shares have been duly authorized and, upon issuance and delivery against payment therefor
in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and non-assessable, (b) provided
that the Warrants have been duly executed and delivered by the Company and duly delivered to the purchasers thereof against payment
therefor, the Warrants, when issued and sold as contemplated in the Registration Statement and Prospectus, will be valid and legally
binding obligations of the Company, enforceable against the Company in accordance with their terms, and (c) the Warrant Shares,
when issued and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinions are subject to:
(i) the effect of bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium or other similar laws relating to or
affecting the rights and remedies of creditors; and (ii) the effect of general principles of equity, whether considered in a proceeding
in equity or at law (including the possible unavailability of specific performance or injunctive relief), concepts of materiality,
reasonableness, good faith and fair dealing, and the discretion of the court before which a proceeding is brought.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the reference
to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and to the filing of this opinion as an exhibit to
a Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the Registration Statement. In
giving this consent, we do not admit that we are &ldquo;experts&rdquo; within the meaning of Section 11 of the Securities Act or
within the category of persons whose consent is required by Section 7 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">&nbsp;/s/ The Matt Law Firm, PLLC</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 60%; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>f8k041819ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED APRIL 17, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><I>Actinium
Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants</I></B></FONT><B><I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK, NY &ndash; April 17, 2019 &ndash;
<B>Actinium Pharmaceuticals, Inc.</B> (NYSE AMERICAN: ATNM) (&ldquo;Actinium&rdquo;) today announced that it intends to offer and
sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its common
stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as
to the actual size or terms of the offering. Actinium intends to use the net proceeds from the sale of the common stock and warrants
to fund its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate Iomab-B and progress Phase 1 trials from its refocused
CD33 program to the proof of concept stage. Actinium will also use the proceeds to support its Antibody Warhead Enabling technology
platform, including its Iomab-ACT program, research and development and general working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">William Blair &amp; Company, L.L.C. is
acting as sole bookrunner for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares and warrants are being offered
pursuant to an effective shelf registration statement (including a prospectus) on Form S-3 (File No. 333-216748) filed with the
U.S. Securities Exchange Commission (the &ldquo;SEC&rdquo;). A preliminary prospectus supplement, dated April 17, 2019 and accompanying
prospectus, dated October 24, 2017, relating to the offering have been filed with the SEC. To obtain a copy of the preliminary
prospectus supplement, dated April 17, 2019, and the final prospectus supplement (when available) for this offering, please contact
William Blair &amp; Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling
(800) 621-0687, or emailing prospectus@williamblair.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patient access and outcomes to cellular
therapies such as BMT or Bone Marrow Transplant and CAR-T with its proprietary ARC or Antibody Radiation-Conjugates targeted conditioning
technology. Actinium&rsquo;s lead product candidate, Iomab-B, is in a pivotal Phase 3 trial for re-induction and conditioning prior
to a BMT for patients with active relapsed or refractory AML or Acute Myeloid Leukemia. BMT is the only curative treatment option
for this patient population and currently no standard of care exists. Actinium&rsquo;s multi-disease, multi-target pipeline of
clinical-stage targeted conditioning ARC&rsquo;s are designed to target the antigens CD45 and CD33 for patients with a broad range
of hematologic malignancies including Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple Myeloma. Actinium is also developing
its proprietary AWE or Antibody Warhead Enabling technology platform which utilizes radioisotopes including iodine-131 and the
highly differentiated actinium-225 coupled with antibodies to target a variety of antigens that are expressed in hematological
and solid tumor cancers. The AWE technology enables Actinium&rsquo;s internal pipeline and with the radioisotope actinium-225 is
being utilized in a collaborative research partnership with Astellas Pharma, Inc. Actinium&rsquo;s clinical programs and AWE technology
platform are covered by a portfolio of over 110 patents covering composition of matter, formulations, methods of use and also methods
of manufacturing the radioisotope Actinium-225 in a cyclotron.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information
in this press release contains forward-looking statements regarding future events, including statements about Actinium&rsquo;s
expectations regarding the terms of the offering or completion of the offering. Actinium intends such forward-looking statements
to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties
related to market and other conditions, the satisfaction of customary closing conditions related to the offering and the impact
of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Actinium
will be able to complete the offering on the anticipated terms, or at all. More information about the risks and uncertainties faced
by Actinium are more fully detailed under the heading &ldquo;Risk Factors&rdquo; in Actinium's Annual Report on Form 10-K for the
year ended December 31, 2018 filed with the SEC. You should not place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Except as required by law, Actinium assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Actinium Pharmaceuticals, Inc.&nbsp;</B><BR>
Steve O'Loughlin<BR>
Principal Financial Officer<BR>
<U>investorrelations@actiniumpharma.com</U></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">Hans
Vitzthum </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal"><U>Hans@LifeSciAdvisors.com</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">(617)
535-7743</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>f8k041819ex99-2_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED APRIL 18, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex99-2_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Actinium Pharmaceuticals, Inc. Announces
Pricing of $16.5 Million Public Offering of Common Stock and Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK, NY &ndash; April 18, 2019 &ndash;
<B>Actinium Pharmaceuticals, Inc.</B> (NYSE AMERICAN: ATNM) (&ldquo;Actinium&rdquo;) today announced the pricing of an underwritten
public offering of 42,860,000 shares of its common stock at a combined public offering price of $0.385 per share of common stock.
The Company also announced the pricing of warrants to purchase up to 42,860,000 shares of common stock at an exercise price of
$0.50 per share and with a term of 5 years commencing on the date of issuance. The offering is expected to close on or about April
23, 2019, subject to the satisfaction of customary closing conditions. The gross proceeds to Actinium from this offering are expected
to be $16.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium.
Actinium intends to use the net proceeds from the sale of the common stock and warrants to fund its ongoing pivotal, Phase 3 SIERRA
trial for its lead product candidate Iomab-B and progress Phase 1 trials from its refocused CD33 program to the proof of concept
stage. Actinium will also use the proceeds to support its antibody warhead enabling technology platform, including its Iomab-ACT
program, research and development and general working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">William Blair &amp; Company, L.L.C. is
acting as sole bookrunner for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares and warrants are being offered
pursuant to an effective shelf registration statement (including a prospectus) on Form S-3 (File No. 333-216748) filed with the
U.S. Securities Exchange Commission (the &ldquo;SEC&rdquo;). A preliminary prospectus supplement, dated April 17, 2019 and accompanying
prospectus, dated October 24, 2017, relating to the offering have been filed with the SEC. To obtain a copy of the preliminary
prospectus supplement, dated April 17, 2019, and the final prospectus supplement (when available) for this offering, please contact
William Blair &amp; Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling
(800) 621-0687, or emailing prospectus@williamblair.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patient access and outcomes to cellular
therapies such as BMT or Bone Marrow Transplant and CAR-T with its proprietary ARC or Antibody Radiation-Conjugates targeted conditioning
technology. Actinium&rsquo;s lead product candidate, Iomab-B, is in a pivotal Phase 3 trial for re-induction and conditioning prior
to a BMT for patients with active relapsed or refractory AML or Acute Myeloid Leukemia. BMT is the only curative treatment option
for this patient population and currently no standard of care exists. Actinium&rsquo;s multi-disease, multi-target pipeline of
clinical-stage targeted conditioning ARC&rsquo;s are designed to target the antigens CD45 and CD33 for patients with a broad range
of hematologic malignancies including Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple Myeloma. Actinium is also developing
its proprietary AWE or Antibody Warhead Enabling technology platform which utilizes radioisotopes including iodine-131 and the
highly differentiated actinium-225 coupled with antibodies to target a variety of antigens that are expressed in hematological
and solid tumor cancers. The AWE technology enables Actinium&rsquo;s internal pipeline and with the radioisotope actinium-225 is
being utilized in a collaborative research partnership with Astellas Pharma, Inc. Actinium&rsquo;s clinical programs and AWE technology
platform are covered by a portfolio of over 110 patents covering composition of matter, formulations, methods of use and also methods
of manufacturing the radioisotope Actinium-225 in a cyclotron.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information
in this press release contains forward-looking statements regarding future events, including statements about Actinium&rsquo;s
expectations regarding the terms of the offering or completion of the offering. Actinium intends such forward-looking statements
to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties
related to market and other conditions, the satisfaction of customary closing conditions related to the offering and the impact
of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Actinium
will be able to complete the offering on the anticipated terms, or at all. More information about the risks and uncertainties faced
by Actinium are more fully detailed under the heading &ldquo;Risk Factors&rdquo; in Actinium&rsquo;s Annual Report on Form 10-K for the
year ended December 31, 2018 filed with the SEC. You should not place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Except as required by law, Actinium assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Actinium Pharmaceuticals, Inc.&nbsp;</B><BR>
Steve O&rsquo;Loughlin<BR>
Principal Financial Officer<BR>
<U>investorrelations@actiniumpharma.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">Hans
Vitzthum </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal"><U>Hans@LifeSciAdvisors.com</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal">(617)
535-7743</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !G J<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***_$/_
M (.:O^":'@']ES]BO5OC3\,]3^(7A+QU<>+[<W[0>,=3N+34_MTLGFJT,\[I
M%AV#+Y00#&W&,8 /V\HK\8?^#27_ (**>(/'G@GQY^S)\4+[4S\0/A?>3ZCI
M2:M,SWKV33^7=VKER6+6UTV>3G;<@#B.OV>H **** "BOY??^#IC_@I#XV^/
M?[;4^@^!M7\1:/\ #3X.7<_@_P#M'3KN6U@U+7MJ2Z@I9&&YHL11;3G;Y3$<
M2<_LO_P1[_X):?##]G/X&_"CXJV$_CC7/B+K?@ZRO;[6-9\5ZC=I.][:12S
M6C3?9E7+D+^[W* /F)YH ^ZZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MSO&'Q$\/_#WP9<^(]?US1]#\/642SW&J:A>QVUG!&Q 5WF<A%4EE )..1ZT
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M/.41JQ8F/(WC&5R,XS0!U5%%% !7YB_\'<__ "AQUK_L:]&_]'-7Z=5^8O\
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M,T[XJ?L<?$Z\9_B-^SWK=XFG-,S;M1TIKEED*%OF9([AMRL>L5Y!C@5]+_\
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MTN_G9&=[R*_O'N=UN[?ZLJD5NK?*,GSE.>U 'IM%%% !7R)XP_X(+_L@^/\
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M45[O,GVI+R]6?<<Y;S!/NR<G)SSDU]A6\"VL"1(-J1J%4>@' KR+^U?C[_T
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MD?:%$CX"XZ^PKURO'_[5^/O_ $ ?A!_X/M1_^0Z/[5^/O_0!^$'_ (/M1_\
MD.@#U\C<,>M?'^M?\$"OV0/$E\USJ7P/\.:E<-G]Y=WM].PR2< O.<#)/ ]:
M]A_M7X^_] 'X0?\ @^U'_P"0Z/[5^/O_ $ ?A!_X/M1_^0Z ,+]E_P#X)=_
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MB95\7:5\/;31_+;=)I&JWEQ<A_X0$EMXUQZ_-0!Z%1110 5Y#\-/^3TOBO\
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M!P[EJ /;_A#XYUKQ[X?N[C7O"]QX4OK6\>W6W>]BO8KN+:CI<12Q\-&RN!R
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M5X%KG[6MQHOPA^%]YI-_HOC?7OBM,K:3>:7IMQ#:369MI+V2\CM#(\[HEN@
MCWAFDDC!9 Q*XFH_M9^.9OA]X*U#P]'X!\7:SXMLK6\L=-TTWHFUB.:]5&N
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MU/Q9)IFE_%/XAZDT37-K?ZI;S:=INVW:S!1QY"W,=@TBIO42"Y945C( 0#Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% B4# 2(  A$! Q$!_\0
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M\\L-I$"&GFFFG>61E*<;_P %9/V9OB7J?["W[1FB_":TN]5\4ZMX$N$LM+L
MS7VKV5EJ6G:IK.BV:H2TESK&BV.H:=;0H=US+<K;)S, =,9Q?X?<29KBJ2H4
MHT\3BE"G5Q&$I8:5;VCITY5E%J$:;J2YJD5-Q=G'GL[VYL9PSQGEV(IXO!U:
ME*@_8^TA0KRJ1H\MO;2Y8N2=DWHEJU:]M5Z/X$_X+8?LAZUJ6FQ:WK'C31?
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MQ+H=E::1=^'_  LNKPQ-=:+I&M'4[EK>6UDU2ZTZ::6UM?Z"_P!G#X_?#O\
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MUCXD^)M9\0SWDM]#/'H?@O0]$U9=*U+QQX_G0?:K/2-&.RRLM-)34]<U9(]
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M\8KW1;?PCX<U8W4CQVM[X>T_7Q'J5YIVH;&;2;W65\.PZJ#&;0LLT3/\A_\
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MTN]:U77$U"6]OY)8E6*Q6"TA_I-_X(^_'/Q!^V?\#+7QA\01')XX\&^-M<\
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MF!IT'AJ.%PKADT*<:6%P\ZE'!QG2JO!TZM:&%=%5JWM/(CX$>%4>'N)^$_\
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MT=+F.RU"SU32='CNX66"\N[:>/)AN+6YFAFC(8%?E(_\$SOVO#G'@MQ@]?\
MA(+7D?0W8_STSVH7_P#P3:_:ST^WDN[SP@\4$0+22'7H'VJ!DD(ETS$@<X4$
M\8P>WR6;1\.LOQ$*N08CAKZW2J)X:MA,5ELZ\:J=H2I2PZIR4W+E<>75NT;M
M-G[;P5'QRJ4H1XCK>)TZ/(G6CF\,[=/E3]Z53ZQA^5*RYI7>EKV1R6D?\$H?
M^";N@:AI.IZ?J7QE-QHVIV&KV<5]\0HKZSDO--NX+VU6[M)=*\NZM_M%O%YU
MM)^[GCW1/E785^L\W[16NZ38PVMA^T%XWAAMH4BA1]&\#S;$C 50=V@ $*HV
MX., !>U?CC>_L?\ QFLFD2\@2T\D,TTEWJ4UO;P[76,F:YD*01#>P7,CJ"3A
M3FNML_\ @G%^U5XIT^"^T'PPFI6EQ&);>XA\16HBFB8966)GNE66-A]V1&*-
MV)"U^2\<U,XQ<\+5S1X^MA:,IPPE7&QKSH4XSM.4*-2K%P7,^5NTVVE%;6/Z
MU\/:T?95::Q//B7!>VA[6,J\I0M?VBOS72NY7BO-:'Z0ZO\ M<^/;(L8/VBO
M%Q4#A6\-^ ST//30>_(/J*\IUK]N?XL6>\6W[1?B9 "2I;PMX!<@\D'+:!C\
M\_B<5\#ZQ_P2C_;:NRWV?X?,Y/0_\)1I@X/KNOUZ?_6KR;6O^"/?[>MWN^S_
M  R,A*D#/B_15Y)S_%JBCWSGC.*^?RS^QWR?68Y<^[K.C9^;4Y):KJ?>8OZZ
MN;V+Q*:5UR*;U=UI9/78^\];_P""B/Q[M ?LG[2^O1[>F_P1\.7Y!QU?0"2#
MQD'J1G@=/(M;_P""GW[3EB6%O^U#J^ /ES\//AFVT\\'/AXY&><=^ASFO@[6
M?^"*O_!1"ZW_ &?X2M(6SC/C;PXG!_W]:7G_ #[UY3K'_!"__@I;>;C!\&MQ
M.< ^//"R^O4MKO8].GK7Z-E;X(]U8JEPQ)/?VWU)VLTKOFK[VZL^9Q2SZS=.
M6:J3_D5=/;=6C9M/9V?Z'W7K7_!6C]KNSW_9OVJ-10@G;N^&/PM?&#W!\/\
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M%.E"WDU"QFN[>..'4+>[M;NSU+2M3CA@6\TJ]MG-O;S_ &B"+^A>"_#^MD.
MH\4<1X=4(5J*KX2-2=*3ITY0<XRK4XU'*C4G%J4(5HPDXM.RDU%?B/'7$V-S
M&:RC)H5)4)U84:M>,6E.JY-<FB<W!M6LKQFURWT/Y]_BU_P1A\5#XO\ BCQ!
M\.=1N+'P%XHUS4=<A\/KI,ETWAVYUB\EO;RPTW48I3'-I"W,\KV<%S%%/91M
M]F66:**%Q^]?[ 'P<M/V./A;H7PZT;SHWAOKS7=6NKDXN=7U?595GU+4KG'
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MU;.,+<PW&F_:5O+6>"6) [F&.LPX$XNRO 3S/&Y+7IX.CG%/A[%3I5L%C*^
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M72]9\:ZX+J&XUU[A)+<Z7I>FWK1W4,]K+,D]EJ$=I?\ @;^V'X6^+'Q(\5_
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MGXNE\#^-_!7C,6!U;1M=BM8[MD6;3YY4GM2KRQ)++!:L\D#LD;VYCE?ZB'
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M[4?QAT7Q_P"*FU1_%&O2Z#\-]4'B(ZUJ4>L:J-5T[4O"]UITHO-3BCO3Y-M
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M-.</=]HJCJ5G-ZS2480C%6BN9M*39T=%%%?D!]>%%%% !1110 4444 %%%%
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MC!_4'L/I4E&!Z45_.?\ 7]>7;R/[M_K^O^!IV204444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "F JX# 2(  A$! Q$!_\0
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MD3KC<H/=2"&!]"*]:5MP!'-?-5:4Z,G":LSW*=2-17B.HHI,X]JR- 9@H)/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?:3>JVZ/RL9W9';%>6WW[4WA%_$6E:1HGG:[-?74=LUQ"#'#$'8+NW,,MUZ
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M]&5/[-M.#]DASU!\I?\ "I)+:.=-DL2RK_==01^M34M.[[BY8K1(I_V59_\
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M4K'.\:LZ ]0&(R!P.GI4\MNDZ;9(UD3^ZXR/R-344KLKECKIN4_[*L\_\><
M_P"V2_X4^6QM[AMTMO%*W3+H"?U%6:*.9]Q<D>Q5CT^UA</':PHXZ,L8!'XX
MI&TVUD=G>TA9FY):,$_GBK=%%WW#DCM8@M[:*V4K%$L0)R0BA1^E3T44BDDM
M$%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI*
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M0WC22ZA?:JZSF-2<!?,8X7 _N]R:[#XQ_$5OA?X"N]<CMQ=709(+>-ON&1^
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MY6U?Y'KY?F>$S2G*K@ZG/&+:>^Z]0HHHKB/4"BBB@ HHHH **** $KR3X[?
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M6]Q&T4@1V1BI&#AE((^H-?G;_P $R=8U63XC^-HV>1M*GL('E7/R>>)#M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"DI:* . ^(G@0ZMMU33 D.K6X.QC]V1>Z/Z@_H>:^7/C_P#9QX%N;_RS:7,5
MS'%/#(,/$^>0?\>XK[?/.0>E<;XR^$/ACQ[?:=<ZUI_VK['.L_DYQ%.5R465
M>CJ"<@'O[9%>]EF9_4I6GK'^M#X?B+AUYMRU</)1J)J]]FO\U_P#Y-_9=_9Y
MUWQCJ5EXRUV>]T?P["PFLK>*0Q3W[ Y#$]4B_5NV!R?N5:2-!&H51M X '04
M^N+'8^KF%7VE7Y+LCW<IRG#Y/0]C06KW?5ON%%%%><>V%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
